A Dark Vector Cognition product
10-K comparison

Healthpeak Properties (DOC) 10-K risk factor changes: FY2025 vs FY2024

The 2025-12-31 10-K against the 2024-12-31 one, compared heading by heading and sentence by sentence.

Item 1A70 rewritten51 added43 removed468 unchanged

All filing items1,482 rewritten979 added882 removed2,336 unchanged

Read the changesGo to Item 1A

Healthpeak Properties Form 10-K, every itemFY2025, filed 3 February 2026, against FY2024, filed 4 February 2025FY2025 on sec.govFY2024 on sec.govRead this filing

Summary

counted, not written

New Item 1A headings (5)

  1. Changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration could adversely affect our business operations or the operations of our tenants or operators.
  2. We depend on real estate investments, particularly in the healthcare property sector, making us more vulnerable to events affecting the healthcare property sector, including a downturn or slowdown in that sector, or laws affecting REIT ownership of healthcare properties.
  3. The pending Janus Living Offering may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.
  4. We will have significant economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living may be limited.
  5. There are conflicts of interest in our relationship with Janus Living and our officers and/or directors who are also officers and/or directors of Janus Living.

Removed Item 1A headings (5)

  1. We depend on real estate investments, particularly in the healthcare property sector, making us more vulnerable to a downturn or slowdown in that specific sector than if we were investing across multiple sectors.
  2. We may be unable to develop, maintain, or expand hospital and health system client relationships.
  3. We could be negatively impacted by legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services or other legislative or regulatory changes affecting REITs or the industries in which we operate.
  4. Changes in federal, state, or local laws or regulations may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate.
  5. We may be unable to fully integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies of the Merger and benefits of property management internalization or do so within the anticipated time frame.
Reworded Item 1A headings (6)
  1. We may be negatively impacted by macroeconomic trends that may increase [added: borrowing,] construction, labor, and other operating [added: or administrative] costs for us and our tenants, operators, and borrowers.
  2. We may invest substantial resources and time in [added: investments or] transactions that are not consummated.
  3. Corporate impact and sustainability commitments and [added: changing] requirements, as well as [added: varying] stakeholder expectations, may impose additional costs and expose us to new risks.
  4. We may be impacted by epidemics, pandemics, or other infectious [removed: diseases, including Covid,] [added: disease outbreaks,] and health and safety measures intended to reduce their spread.
  5. Our [added: past] participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs could subject us or our operators to disruptive government and financial audits, enforcement actions, and recovery activity.
  6. Increased [added: interest rates and] borrowing costs could materially adversely impact our [added: business and] ability to refinance existing debt, sell properties, and conduct investment activities.

A heading is new when no FY2024 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.

Sentences by item

24 items, with every count and a link to each item that changed

Underlined words on a shaded ground are new in FY2025; struck-through words were in FY2024. Sentences that are wholly new or wholly gone are labelled rather than marked.

Item 1A. Risk Factors

70 rewritten, 51 added, 43 removed, 468 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

We may be negatively impacted by macroeconomic trends that may increase [added: borrowing,] construction, labor, and other operating [added: or administrative] costs for us and our tenants, operators, and borrowers.

Rewritten

In recent periods, many of our costs, including [removed: labor costs, construction costs,] [added: borrowing, construction, labor,] utilities, and other operating and administrative costs, have been adversely affected by macroeconomic trends, including [added: higher interest rates,] inflation, price volatility, [removed: declines in economic growth rates,] and changes in [removed: unemployment.][added: unemployment, among other factors.]

Rewritten

These macroeconomic trends [added: may also negatively impact consumer confidence and spending and] have been exacerbated [added: at times] by [removed: higher interest rates,] [added: domestic and international policy shifts; uncertainty in the regulatory landscape in which we, our tenants, and our operators operate;] supply chain [removed: disruptions,] [added: disruptions;] geopolitical [removed: conflicts,] [added: conflicts;] federal government [removed: deficits, responses to the Covid pandemic,] [added: deficits;] and other international and domestic events impacting the macroeconomic environment.

Rewritten

Interest rates may [removed: continue to] remain elevated above historical levels for [removed: the foreseeable future] [added: extended periods] or rise again.

Rewritten

The FOMC may [removed: maintain] [added: not reduce the federal funds rate in the amounts or on the timeline currently anticipated, which could result in] a higher federal funds rate for a longer period of time, or [added: the FOMC] may determine to raise the federal funds rate again, either of which would likely lead to higher short-term interest rates and the possibility of lower asset values, slowing economic growth and increasing the possibility of a recession.

Rewritten

We [added: currently have and] may [added: incur additional debt obligations that have variable interest rates and related payments that vary with the movement of certain indices, and we may] not be able to offset additional costs caused by inflation, higher interest rates, or other macroeconomic trends by passing them through, or increasing the rates we charge, to tenants and residents.

Rewritten

These increased costs [added: have caused, and in the future] may [added: cause, unfavorable financing terms and may] hinder our ability to execute on accretive acquisitions or otherwise adversely affect our business, results of operations, and financial condition.

Rewritten

[removed: Increased] [added: Elevated] interest rates could also negatively impact consumer spending and our tenants’, operators’, and borrowers’ businesses and future demand for our properties.

Rewritten

Additionally, changing [removed: technologies, political and regulatory conditions,] [added: technologies] and cultural trends could negatively impact future demand for our properties, which could have a material adverse effect on our business, results of operations, and financial condition.

Rewritten

Finally, our lab investments could also be adversely affected if the life science industry migrates from the U.S. to other countries [added: that have seen accelerated growth in the biotech industry,] or to areas outside of our primary lab markets in the greater South San Francisco, San Diego, and Boston areas.

Rewritten

- significant funding requirements, including for rent payments due to [removed: us;][added: us that may not be available;]

Rewritten

- intellectual property and technology risks under patent, copyright, and trade secret laws; [removed: and]

Rewritten

- economic conditions potentially restricting growth [removed: opportunities.][added: opportunities; and]

Rewritten

Our lab tenants’ ability to raise capital depends on the actual or perceived viability of their products and technologies, their financial and operating condition and outlook, and the overall financial, banking, [added: regulatory,] and economic environment.

Rewritten

If venture capital firms, private investors, the public markets, companies in the life science industry, the government, or other sources of funding are difficult to obtain or unavailable to support our tenants’ activities, including as a result of [added: changes to regulatory policies and actions by the U.S. political administration (including those described earlier),] general economic [removed: conditions or] [added: conditions,] adverse market [removed: conditions] [added: conditions, or uncertainty] that negatively impact our tenants’ ability to raise capital, our tenants’ business would be adversely affected or could fail.

Rewritten

If our lab tenants’ businesses are adversely affected, they may [removed: fail] [added: be unable] to [removed: make] [added: meet] their [removed: rent payments] [added: financial obligations] to [removed: us,] [added: us or expand within our properties,] which could have a material adverse effect on our business, results of operations, and financial condition.

Rewritten

Occupancy levels at, and rental income from, our outpatient medical [added: facilities] and senior housing properties depend on our ability and the ability of our tenants, operators, and borrowers to compete with respect to (i) the quality of care provided, (ii) reputation, (iii) price, (iv) the range of services offered, (v) the physical appearance of a property, (vi) family preference, (vii) referral sources, and (viii) location.

Rewritten

In addition, our [removed: outpatient medical and senior housing] tenants, operators, and borrowers compete with certain companies that [removed: have superior resources and attributes and/or] provide similar healthcare services or alternatives such as home health agencies, telemedicine, life care at home, community-based service programs, retirement communities, and convalescent centers.

Rewritten

A shortage of care givers or other trained personnel, [added: shifts in immigration policy,] union activities (including strikes, labor slowdowns, or contract negotiations), wage laws, or general inflationary pressures on wages may require our tenants, operators, and borrowers to enhance pay and benefits packages, or to use more expensive contract personnel, and they may be unable to offset these added costs by increasing the rates charged to residents or patients.

Rewritten

A downturn in our tenants’, operators’, or borrowers’ businesses has led, and could in the future lead, to voluntary or involuntary bankruptcy or similar [added: reorganization, restructuring, or] insolvency proceedings, including assignment for the benefit of creditors, liquidation, or winding-up.

Rewritten

We depend on real estate investments, particularly in the healthcare property sector, making us more vulnerable to [added: events affecting the healthcare property sector, including] a downturn or slowdown in that [removed: specific sector than if we were investing across multiple sectors.][added: sector, or laws affecting REIT ownership of healthcare properties.]

Rewritten

[removed: In addition, such downturns] [added: Such events impacting the healthcare property sector] could have a material adverse effect on [added: our ability to participate in] the [added: ownership of or investment in healthcare real estate, the] value of our [removed: properties and] [added: properties, or] our ability to sell properties at prices or on terms acceptable or favorable to us.

Rewritten

- legal and regulatory hurdles, including moratoriums on development and redevelopment activities, [added: climate regulatory requirements or expectations (such as] net zero or carbon [removed: neutrality requirements,] [added: neutrality),] or other building and energy performance requirements;

Rewritten

- other factors over which we have limited or no control, including: (i) changes in market and economic conditions; (ii) [added: decline in demand, including after construction has commenced; (iii)] natural disasters and other catastrophic events or physical climate risks, such as [added: floods,] wildfires, earthquakes, and wind storms; [removed: (iii)] [added: (iv)] pandemics or other health crises; [removed: (iv)] [added: (v)] labor conditions, including a labor shortage or work stoppage; [removed: (v)] [added: (vi)] shortages of construction materials; [removed: (vi)] [added: (vii)] environmental conditions; or [removed: (vii)] [added: (viii)] civil unrest and acts of war or terrorism.

Rewritten

As a result, we have limited rights to direct or influence the business or operations of our [removed: CCRCs and in the properties owned by our SWF SH JV,] [added: senior housing properties,] all of which are under RIDEA structures, and we depend on our operators to operate these properties in a manner that complies with applicable law, minimizes legal risk, and maximizes the value of our investment.

Rewritten

Operators of our [removed: CCRCs and the SWF SH JV] [added: senior housing] properties primarily depend on private sources for their revenues and the ability of their patients and residents to pay fees.

Rewritten

As a result, we may determine to self-insure more of our exposures, absorb more [removed: below deductible] [added: below-deductible] losses, and look for alternative means of risk transfer in order to avoid spiraling insurance costs.

Rewritten

In particular, (i) a significant portion of our lab development projects and approximately [removed: 67%] [added: 69%] of our lab portfolio (based on gross asset value as of December 31, [removed: 2024)] [added: 2025)] was concentrated in California, which is known to be subject to earthquakes, wildfires, and other natural disasters, and (ii) approximately [removed: 68%] [added: 69%] of our [removed: CCRC] [added: life plan community] portfolio (based on gross asset value as of December 31, [removed: 2024)] [added: 2025)] was concentrated in Florida, which is known to be subject to hurricanes.

Rewritten

Similarly, a hurricane in Florida could damage a significant portion of our [removed: CCRC] [added: life plan community] portfolio.

Rewritten

Our insurance coverage does not include damages as a result of a [removed: pandemic (such as Covid),] [added: pandemic,] including business interruption, loss of revenue or earnings, or any related effects (e.g., increased costs related to personal protective equipment, sanitization/sterilization of surfaces and equipment, and additional staffing).

Rewritten

Our [removed: CCRC and] senior housing operators also face various forms of class-action lawsuits from time to time, such as wage and hour and consumer rights actions, which generally are not covered by insurance.

Rewritten

If inflation exceeds our annual escalations, [removed: as it often recently has,] our growth and profitability may be limited.

Rewritten

Furthermore, if economic conditions result in significant increases in the Consumer Price Index, but the escalations under our leases with contingent rent escalators are capped or the increase in the Consumer Price Index exceeds our tenants’ ability to pay, our growth and profitability [removed: also] may [added: also] be limited.

Rewritten

Because many of the properties securing our mortgage loans are [removed: licensed senior housing] health care facilities, we [removed: would also] [added: may] need to navigate and comply with various healthcare regulatory matters in a variety of states in connection with any foreclosure effort.

Rewritten

We may invest substantial resources and time in [added: investments or] transactions that are not consummated.

Rewritten

We regularly review potential [added: investments and] transactions in order to maximize stockholder value.

Rewritten

Our review process may require significant management attention, and a potential transaction could be abandoned or rejected by us or the other parties involved after we expend significant [removed: resources] [added: expenses, resources,] and time.

Rewritten

Furthermore, with respect to our [removed: CCRC properties and the properties in our SWF SH JV,] [added: senior housing properties,] all of which are operated in RIDEA structures, we generally directly bear the costs of any such increases in litigation, monitoring, reporting, and insurance due to our direct exposure to the cash flows of such properties.

Rewritten

Unfavorable resolution of any such litigation, including an outsized jury verdict, [added: particularly if it exceeds our insurance policy limits] or [added: is not covered by insurance at all, or] negative publicity as a result of such litigation could have a material adverse effect on our business, results of operations, and financial condition.

Rewritten

In addition, the presence of contamination or the failure to remediate contamination may [removed: materially] adversely affect our ability to use, develop, sell, or lease the property or to borrow using the property as collateral.

New in FY2025

- risks related to the pending Janus Living Offering and our relationship with Janus Living if the Janus Living Offering is completed; and

New in FY2025

Changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration could adversely affect our business operations or the operations of our tenants or operators.

New in FY2025

Recent and ongoing changes in U.S. federal government policy have introduced uncertainty to the capital markets, as well as within our industry and the industries of our tenants and operators.

New in FY2025

These policy changes include, but are not limited to, workforce reductions at federal agencies; executive actions impacting National Institutes of Health (“NIH”) grant funding; changes to visa policies affecting the scientific workforce; efforts to cap NIH indirect cost reimbursements; tariffs and potential tariff actions; and changes to drug pricing policies.

New in FY2025

For example, recent policy shifts and administration priorities affecting research funding, drug pricing, drug review and approval processes, and tariffs, among other policies, have created uncertainty in the life science ecosystem in which our lab tenants operate.

New in FY2025

This uncertainty has adversely impacted, and in the future may adversely impact, the ability of life science companies obtain investor funding, which could lead to setbacks in research and development timelines, advancement of drug pipelines, or achievement of commercial viability.

New in FY2025

In addition, competitive international biotech sectors, including in China, supported by favorable regulatory conditions and costs there, may also divert research and development activity and investment away from the U.S., reducing long-term demand for domestic life science real estate.

New in FY2025

These policy shifts and other dynamics may affect our lab tenants’ ability to make rent payments to us or expand within our properties, which, as a result, could negatively impact our operating and financial results.

New in FY2025

Furthermore, reductions in Medicaid spending and cuts to Medicaid provider rates, the expiration of health insurance subsidies under the Patient Protection and Affordable Care Act, along with the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), other potential changes to federal reimbursement policies, and other potential policy initiatives focused on medical care, including site-neutral payments and changes to reimbursement for certain outpatient services, could reduce patient volumes, increase uncompensated care, and put downward pressure on reimbursement rates for hospitals and outpatient medical facilities, which could have an adverse effect on our tenants’, operators’, and borrowers’ liquidity, financial condition, or results of operations.

New in FY2025

In general, facilities in non-expansion states face a significantly higher financial risk due to Medicare / Medicaid and Affordable Care Act provisions in the One Big Beautiful Bill Act (“OBBA”).

New in FY2025

An expansion state is a U.S. state that chose to expand its Medicaid program under the Affordable Care Act, thereby extending coverage to nearly all low-income adults up to 138% of the federal poverty level and becoming eligible for enhanced federal funding.

New in FY2025

In contrast, a non-expansion state is a state that did not expand its Medicaid program under the Affordable Care Act.

New in FY2025

As Affordable Care Act subsidies have expired, non-expansion states with higher numbers of individuals not eligible for Medicaid who can no longer rely on purchasing coverage from the Affordable Care Act marketplace will be disproportionately affected unless the subsidies are extended.

New in FY2025

Accordingly, facilities in non-expansion states could face challenges in meeting operational costs if patients/residents lose the ability to purchase Affordable Care Act coverage.

New in FY2025

Because our outpatient medical segment depends on stable, long-term occupancy by healthcare providers, such adverse changes in U.S. healthcare policy could adversely affect our operating and financial results.

New in FY2025

Tariffs and potential tariff actions have also led to market volatility, higher construction costs, and supply chain disruptions, which could delay or increase the cost of our development projects and impair our access to capital.

New in FY2025

- new or emerging technologies, such as artificial intelligence and automation, that introduce advanced computational technologies into tenants’ research and development programs, which could accelerate and streamline a number of research and development functions and lead to a reconfiguration in space requirements by our tenants or decrease in demand for space over time.

New in FY2025

In addition, several of our lab tenants build upon the earlier successful research conducted at research institutions and funded by NIH grants; sustained funding cuts to NIH grants could have long-lasting impacts to the industry and impede our tenants’ ability to build on such earlier successful research.

New in FY2025

Our tenants could also be adversely affected by tariffs, which could cause the import or export of materials, components, or specialized equipment they use to become prohibitively expense to use or sell.

New in FY2025

Additionally, at various times, legislation potentially limiting REIT ownership and investment in the healthcare property sector has been introduced or is under discussion at the federal, state, and/or local level, including laws that would restrict REIT investment in the sector, reduce tax benefits for REITs that own healthcare properties, or require burdensome approvals for, or significantly delay the ability of, healthcare entities to transact with REITs.

New in FY2025

We use generative artificial intelligence and/or machine learning (collectively, “AI”) tools in our investment and capital allocation decisions and operations, including commercially available AI applications or AI features available through our existing software or technology platforms.

New in FY2025

New laws and regulations governing AI use are being adopted, and existing laws and regulations may be interpreted in ways that would affect our business operations and the way in which we use AI.

New in FY2025

While we have adopted a governance framework concerning use of AI tools and provide training to our employees to guard against the aforementioned risks, there can be no assurance that we will realize the anticipated benefits or mitigate such risks of using AI tools.

New in FY2025

The adoption of AI tools by our tenants may also lead to a reconfiguration in space requirements by our tenants or decreased in demand for space over time.

New in FY2025

If we are not able to offset any material reduction in demand through leasing or re-leasing efforts, repurposing space, property dispositions, or other means, there could be a material adverse effect on our business, results of operations, and financial condition.

New in FY2025

Risks Related to the Pending Janus Living Offering and Our Relationship with Janus Living if the Janus Living Offering is Completed

New in FY2025

The pending Janus Living Offering may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.

New in FY2025

In December 2025, we confidentially submitted a draft registration statement on Form S-11 to the SEC relating to the proposed Janus Living Offering.

New in FY2025

Although we expect to complete the Janus Living Offering in the first half of 2026, unforeseen developments, including related to market conditions, receipt of regulatory approvals, completion of related financings, completion of the SEC’s review, and other customary closing conditions, could delay or prevent the Janus Living Offering or cause it to occur on terms or conditions that are less favorable or different than anticipated.

New in FY2025

The conditions required to complete the Janus Living Offering may not be satisfied on the timeline anticipated or at all.

New in FY2025

In addition, expenses incurred to accomplish the Janus Living Offering could be significantly higher than we currently anticipate.

New in FY2025

We may not realize the expected benefits of the Janus Living Offering, including due to macroeconomic trends that may increase operating costs; the effects of economic conditions and market conditions in the markets in which we operate and in which Janus Living will operate; our concentration of real estate investments in the healthcare property sector and Janus Living’s planned concentration of real estate investments in the senior housing sector, which makes us and Janus Living more vulnerable to a downturn in those specific sectors than if we and Janus Living invested across multiple sectors; or a lack of recognition by the market of the value of our senior housing portfolio.

New in FY2025

In addition, the Janus Living Offering may demand significant time and attention from our senior management and employees and may divert their attention from operating and growing our business.

New in FY2025

We will have significant economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living may be limited.

New in FY2025

Following the Janus Living Offering, we intend to externally manage and retain a substantial majority interest in Janus Living, with new public shareholders owning the remaining interest.

New in FY2025

We will also be entitled to nominate certain directors for election to Janus Living’s board of directors.

New in FY2025

As the majority owner of Janus Living common stock, we will have a significant economic exposure to shifts in the price of Janus Living common stock, which may not correspond to the financial performance of Janus Living.

New in FY2025

As a publicly traded security, the market price and liquidity of the market for shares of Janus Living common stock may be significantly affected by numerous factors, including market volatility, some of which are beyond our control and the control of Janus Living and may not be directly related Janus Living operating performance.

New in FY2025

In the future, we may be unable to dispose of shares of Janus Living common stock on favorable terms, which may adversely affect the value we realize from our investment in Janus Living.

New in FY2025

In addition, if we were to cease to serve as external manager to Janus Living, our ability to control the assets and activities of Janus Living may be limited.

Dropped from FY2024

- risks related to the regulatory environment;

Dropped from FY2024

- risks relating to integration and property management internalization following our Merger with Physicians Realty Trust;

Dropped from FY2024

Interest rates rose substantially in 2022 and 2023.

Dropped from FY2024

Historically higher interest rates have caused, and may in the future cause, unfavorable financing terms and increased interest costs for variable rate debt and new debt.

Dropped from FY2024

We may be unable to develop, maintain, or expand hospital and health system client relationships.

Dropped from FY2024

We invest significant time in developing, maintaining, and expanding relationships with both new and existing hospital and health system clients.

Dropped from FY2024

If we fail to maintain these relationships, including through a lack of responsiveness, failure to adapt to the current market, or employment of individuals with inadequate experience, our reputation and relationships will be harmed and we may lose business to competitors, which could have a material adverse effect on us.

Dropped from FY2024

Under certain leases, a portion of the tenant’s rental payment to us is based on the property’s revenues (i.e., contingent rent).

Dropped from FY2024

If a tenant’s revenue at a rental property with contingent rent declines, our rental revenues would decrease.

Dropped from FY2024

For additional information on risks related to integration following the Merger, see “—Risks Relating to Integration following our Merger with Physicians Realty Trust” below.

Dropped from FY2024

We may use generative artificial intelligence and/or machine learning (collectively, “AI”) tools in our operations.

Dropped from FY2024

We currently have and may incur additional debt obligations that have variable interest rates and related payments that vary with the movement of certain indices.

Dropped from FY2024

During inflationary periods, interest rates have historically increased.

Dropped from FY2024

For example, actions taken by the FOMC in response to recent inflationary conditions led to rising interest rates, which may continue to remain at elevated levels for the foreseeable future.

Dropped from FY2024

Elevated interest rates result in increased interest costs for our variable rate debt and our new debt, which adversely affects our cost of capital and makes the financing of any acquisition and development activity more costly.

Dropped from FY2024

Risks Related to the Regulatory Environment

Dropped from FY2024

See “Item 1, Business—Government Regulation, Licensing and Enforcement—Healthcare Licensure and Certificate of Need” for a discussion of certain of these laws and regulations.

Dropped from FY2024

In particular, several state and local governments implemented eviction moratoriums as a result of the Covid pandemic that applied to both residential and commercial tenants.

Dropped from FY2024

Although these moratoriums have generally terminated or expired, federal, state, and local governments could enact moratoriums under similar circumstances in the future.

Dropped from FY2024

The status of the Patient Protection and Affordable Care Act, along with the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”) and related regulations may be subject to change, and other health reform measures could be implemented as a result of political, legislative, regulatory, and administrative developments and judicial proceedings, including those with far reaching implications and effecting fundamental changes in the healthcare system.

Dropped from FY2024

Federal and state authorities may continue to implement new or modified reimbursement methodologies that may negatively impact health care property operations.

Dropped from FY2024

There can be no assurance that adequate reimbursements will be available for services provided by our operators and tenants.

Dropped from FY2024

We could be negatively impacted by legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services or other legislative or regulatory changes affecting REITs or the industries in which we operate.

Dropped from FY2024

Congressional consideration of legislation pertaining to the federal debt ceiling, the Affordable Care Act, tax reform, and entitlement programs, including reimbursement rates for physicians, could have a material adverse effect on our tenants’, operators’, and borrowers’ liquidity, financial condition, or results of operations.

Dropped from FY2024

Any shutdown of the federal government that delays or disrupts payments or any other material adverse effect on payments to our tenants, operators, or borrowers could adversely affect their ability to satisfy their obligations to us and could have a material adverse effect on us.

Dropped from FY2024

In addition, changes in federal, state, or local laws affecting the healthcare or life sciences industries, particularly that apply to REITs, or changes in the scope, interpretation, or enforcement of the related regulatory frameworks could adversely affect us or our tenants, operators, or borrowers.

Dropped from FY2024

Changes in federal, state, or local laws or regulations may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate.

Dropped from FY2024

Changes in federal, state, or local laws or regulations, including changes limiting REIT investment in the healthcare sector, reducing healthcare-related tax benefits for REITs, or requiring additional approvals for healthcare entities to transact with REITs, could have a material adverse effect on our ability to participate in the ownership of or invest in healthcare providers and healthcare real estate.

Dropped from FY2024

Legislation potentially impacting REIT ownership and investment in the healthcare sector has recently been introduced or is under discussion at the federal and state level.

Dropped from FY2024

Such legislation or similar laws or regulations, if enacted, could have a material adverse impact on our business.

Dropped from FY2024

Risks Relating to Integration and Property Management Internalization Following the Merger

Dropped from FY2024

We may be unable to fully integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies of the Merger and benefits of property management internalization or do so within the anticipated time frame.

Dropped from FY2024

We have benefited from, and expect to continue to benefit from, the synergies from our Merger with Physicians Realty Trust as a result of (i) the elimination of duplicative costs associated with supporting an additional public company platform, (ii) internalization of the property management function, and (iii) leveraging state-of-the-art technology and systems.

Dropped from FY2024

However, we continue to devote significant management attention and resources to integrating the operations of the Company and Physicians Realty Trust and internalizing the property management function.

Dropped from FY2024

Potential difficulties we may encounter in the ongoing integration process include the following:

Dropped from FY2024

- the inability to successfully combine the operations of the Company and Physicians Realty Trust, including the integration of employees, customer records and maintaining cybersecurity protections, in a manner that permits us to achieve the cost savings anticipated from the Merger, which would result in the anticipated benefits of the Merger not being realized in the time frame currently anticipated or at all;

Dropped from FY2024

- the inability to dispose of assets or operations that we desire to dispose of;

Dropped from FY2024

- the complexities associated with managing the combined businesses out of different locations and integrating personnel from the two companies;

Dropped from FY2024

- the failure to retain key employees of either of the two companies;

Dropped from FY2024

- potential disruptions and performance shortfalls due to the failure to successfully internalize the property management function;

An excerpt. Shown here: 40 of 70 rewritten, 40 of 51 added and 40 of 43 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2025 filing and the FY2024 filing.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

184 rewritten, 198 added, 75 removed, 319 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

This section generally discusses the results of our operations for the year ended December 31, [removed: 2024] [added: 2025] compared to the year ended December 31, [removed: 2023.][added: 2024.]

Rewritten

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, [removed: 2023] [added: 2024] filed with the SEC on February [removed: 9, 2024.][added: 4, 2025 for a discussion of the year ended December 31, 2024 compared to the year ended December 31, 2023.]

Rewritten

[removed: Increased interest rates, ongoing geopolitical tensions, and volatility] [added: In addition, uncertainty] in public and private equity and fixed income markets [added: and elevated interest rates] have [added: directly] led to increased costs and limitations on the availability of [removed: capital.][added: capital to us.]

Rewritten

[removed: In addition, increased] [added: Elevated] interest rates have and could continue to adversely impact our borrowing costs, the fair value of our fixed rate instruments, transaction volume, and real estate values generally, including our real estate.

Rewritten

To the extent our tenants and/or operators have [removed: also experienced] [added: experienced, or will experience,] increased costs, liquidity constraints, and financing difficulties due to the foregoing macroeconomic and market conditions, they may be unable or unwilling to make payments or perform their obligations when [removed: due.][added: due, and occupancy of our properties could be adversely affected.]

Rewritten

We have also been affected by increased costs relating to tenant improvements and construction, which, together with higher costs of [removed: capital,] [added: capital and tariff actions (or potential tariff actions),] have adversely affected, and in the future may adversely affect, [added: construction starts and] the expected yields on our [removed: development] [added: capital projects, including our developments] and [removed: redevelopment projects.][added: redevelopments.]

Rewritten

These events [removed: include] [added: include,] but are not limited [removed: to] [added: to, the following, any of which could negatively impact our business:] inflation; [added: recession;] interest rates; challenges in the financial markets; [added: availability of private capital] and [removed: changes] [added: funding] in the [added: life science industry; and actions by the] U.S. political [removed: administration, which could] [added: administration and regulatory agencies that] affect healthcare policy, [added: life science research and innovation,] labor supply, procurement and construction costs, and [added: general] economic [removed: conditions, among other things.][added: conditions (such as budget reconciliation actions, tariff actions, changes in healthcare regulation, decreases in government funding and staffing, and immigration reform).]

Rewritten

- [removed: In January 2024, we sold] a [added: decrease in gain upon change of control related to the sale of a] 65% interest in two lab buildings in San Diego, California [removed: (the “Callan Ridge JV”)] to a third-party [removed: for net proceeds of $128 million.][added: in January 2024;]

Rewritten

[removed: - During] [added: Gain on sales of real estate, net decreased during] the year ended December 31, [removed: 2024, we sold:] [added: 2025 primarily as a result of the $72 million gain on sales from:] (i) [added: one outpatient medical land parcel for proceeds of $4 million, (ii) nine outpatient medical buildings for proceeds of $160 million, and (iii)] a portfolio of [removed: 61] [added: 16] outpatient medical buildings for [removed: $697 million and provided] [added: $182 million, which were sold during] the [removed: buyer with a mortgage loan secured by] [added: year ended December 31, 2025, as compared to] the [removed: real estate] [added: $179 million gain on sales from: (i) a portfolio of 61 outpatient medical buildings] sold for [removed: $419] [added: proceeds of $697] million, (ii) 14 outpatient medical buildings [added: sold] for [added: proceeds of] $220 million, (iii) a portfolio of seven lab buildings [added: sold] for [added: proceeds of] $180 million, and [removed: (iv)] [added: (vi)] a portfolio comprised of a land parcel and various vacant buildings on certain of our [removed: CCRC] [added: life plan community] campuses [added: sold] for [added: proceeds of] $12 [removed: million.][added: million, which were sold during the year ended December 31, 2024.]

Rewritten

- During the year ended December 31, [removed: 2024,] [added: 2025,] the following projects were placed in service: (i) a portion of [removed: two] [added: three] lab development projects with total project costs of [removed: $83] [added: $162] million, (ii) two outpatient medical development projects with total project costs of [removed: $62] [added: $73] million, (iii) [removed: one outpatient medical] [added: two lab] development [removed: project] [added: buildings] held in [removed: a consolidated joint venture] [added: our unconsolidated Callan Ridge JV] of which our share of total project costs was [removed: $22] [added: $63] million, (iv) [removed: one] [added: a portion of two outpatient medical development projects with total project costs of $32 million, (v) two] lab redevelopment [removed: building] [added: buildings] held in [removed: one of] our unconsolidated South San Francisco JVs of which our share of total project costs was [removed: $15] [added: $26] million, [removed: (v) one] [added: (vi) three] lab redevelopment [removed: project] [added: projects] with total project costs of [removed: $14] [added: $23] million, [removed: (vi)] [added: (vii)] a portion of [removed: one] [added: two] lab redevelopment [removed: project] [added: projects] with total project costs of [removed: $13] [added: $20] million, and [removed: (vii) a portion of] [added: (viii)] one [removed: lab] [added: outpatient medical] redevelopment [removed: building held in one of our unconsolidated South San Francisco JVs of which our share of] [added: project with] total project costs [removed: was $9] [added: of $12] million.

Rewritten

- During the year ended December 31, [removed: 2024,] [added: 2025,] we repurchased [removed: 10.5] [added: 5.09] million shares of our common stock under [removed: our 2022] [added: the 2024] Share Repurchase Program (as defined below) at a weighted average price of [removed: $17.98] [added: $18.50] per share for a total of [removed: $188] [added: $94] million.

Rewritten

[removed: Quarterly common] [added: Common] stock cash dividends [removed: paid] during [removed: 2024] [added: 2025] aggregated to [removed: $1.20] [added: $1.22] per share.

Rewritten

[removed: On] [added: In] February [removed: 3,] 2025, our Board of Directors declared [removed: a] [added: an increase in the] quarterly common stock cash [removed: dividend of] [added: dividend, from $0.300 to] $0.305 per share, [removed: reflecting] [added: resulting in] an [removed: increase from $0.30 to $0.305] [added: annualized dividend of $1.220] per share.

Rewritten

Our [removed: CCRCs] [added: senior housing properties] are operated through RIDEA structures.

Rewritten

The [removed: SWF SH JV and] loans [removed: receivable] [added: receivable, preferred equity investment and the three other properties] are non-reportable segments that have been presented on a combined basis herein.

Rewritten

Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, [added: operator transition costs, and] actuarial reserves for insurance claims that have been incurred but not [removed: reported, and the impact of deferred community fee income and expense.][added: reported.]

Rewritten

As described in Note 16 to the Consolidated Financial Statements, our [removed: chief operating decision maker (“CODM”)] [added: CODM] evaluates the performance of our operating segments based on Adjusted NOI.

Rewritten

[removed: Our] [added: Certain of our] operating segments are [removed: aggregated into] reportable segments for which we disclose Total Portfolio Adjusted [removed: NOI for our reportable segments.][added: NOI.]

Rewritten

Operating expenses generally relate to leased outpatient medical and lab buildings, as well as [removed: CCRC] [added: senior housing] facilities.

Rewritten

A property is removed from Merger-Combined Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event [added: or has a planned operator transition] that significantly impacts operations, or a significant tenant relocates from a Merger-Combined Same-Store property to a Merger-Combined non Same-Store property and that change results in a corresponding increase in revenue.

Rewritten

The Company was provided access to the underlying financial statements of legacy Physicians Realty Trust [removed: (which financial statements have been audited or, in the case of interim periods, reviewed)] and other detailed information about each property, such as the acquisition date.

Rewritten

As a result of the Merger, approximately [removed: 97%] [added: 95%] of the combined portfolio is represented in the Merger-Combined Same-Store presentation for the outpatient medical segment for the year ended December 31, [removed: 2024.][added: 2025.]

Rewritten

Funds from Operations (“FFO”), as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real [removed: estate,] [added: estate or land held for development,] plus real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO from joint ventures.

Rewritten

*FFO as Adjusted.* In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, [removed: transaction] [added: transaction, merger,] and [removed: merger-related items,] [added: restructuring-related costs,] other impairments (recoveries) and other losses (gains), [removed: restructuring and severance-related charges,] prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”).

Rewritten

These adjustments are net of tax, when applicable, and are reflective of our share of our joint [added: ventures.]

Rewritten

See “Nareit FFO” above for further disclosures regarding our [removed: use of pro rata share information and its limitations.]

Rewritten

Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including [removed: goodwill, undeveloped land parcels,] [added: goodwill] and loans receivable.

Rewritten

Comparison of the Year Ended December 31, [removed: 2024] [added: 2025] to the Year Ended December 31, [removed: 2023][added: 2024]

Rewritten

The following table summarizes results for the years ended December 31, [removed: 2024] [added: 2025] and [removed: 2023(1)] [added: 2024(1)] (in thousands):

Rewritten

| | | | | | | [removed: 2024] [added: 2025] | | | | | | [removed: 2023] [added: 2024] | | | | | | | | | | | | | | | | | | Change | | |

Rewritten

| Net income (loss) applicable to common shares | | | [removed: | | |] $ | [removed: 242,384] [added: 70,513] | | | | | $ | [removed: 304,284 | | | | | | | | | | | |] [added: 242,384] | | | | | $ | [removed: (61,900)] [added: 304,284] | |

Rewritten

| Nareit FFO [removed: | | | | | | 1,092,730 | | | | | | 985,180 | | |] [added: applicable to common shares] | | | [added: 1,268,981] | | | | | | [added: 1,092,730] | | | | | | [removed: 107,550] [added: 985,180] | | |

Rewritten

| FFO as Adjusted [removed: | | | | | | 1,231,868 | | | | | | 978,306 | | |] [added: applicable to common shares] | | | [added: $] | [added: 1,292,256] | | | | | [added: $] | [added: 1,231,868] | | | | | [removed: 253,562] [added: $] | [added: 978,306] | |

Rewritten

| AFFO [removed: | | | | | | 1,140,665 | | | | | | 884,230 | | |] [added: applicable to common shares] | | | [added: 1,183,568] | | | | | | [added: 1,140,665] | | | | | | [removed: 256,435] [added: 884,230] | | |

Rewritten

[removed: *•*an] [added: - an] increase in [removed: depreciation, primarily as a result of:] [added: depreciation related to:] (i) assets acquired as part of the Merger and (ii) development and redevelopment projects placed in service during [removed: 2023] [added: 2024] and [removed: 2024;][added: 2025.]

Rewritten

[removed: - an increase] [added: *•*a decrease] in transaction and merger-related [removed: costs, primarily as a result of] costs incurred in [added: 2025 compared to 2024 in] connection with the Merger;

Rewritten

*•*an increase in interest [removed: expense, primarily as a result of:] [added: expense related to:] (i) debt assumed as part of the Merger, including $1.25 billion aggregate principal amount of senior unsecured notes, $400 million aggregate principal amount of [removed: senior unsecured term loans assumed as part of] the [removed: Merger (the “2028] [added: 2028] Term [removed: Loan”),] [added: Loan,] and $128 million aggregate principal amount of mortgage [removed: debt and] [added: debt,] (ii) borrowings under the 2029 Term Loan, which closed in March [removed: 2024;][added: 2024, (iii) the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035, which closed in February 2025, (iv) the issuance of $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033, which closed in August 2025, and (v) higher borrowings under the commercial paper program;]

Rewritten

[removed: - an increase in impairments] [added: Impairments] and loan loss reserves (recoveries), [removed: net,] [added: net decreased for the year ended December 31, 2025] primarily as a result of: (i) impairment charges associated with an asset impaired under the held for sale model [added: that was recognized in 2024] and (ii) [removed: an increase] [added: a decrease] in loan loss reserves [added: under the current expected credit losses model, which is primarily due to (i) reserves] recognized [added: in 2024] on [removed: secured] loans [removed: and mezzanine loans] receivable acquired as part of the [removed: Merger;][added: Merger, (ii) changes in operating performance and fair values of the underlying collateral of the Company’s loans receivable and (iii) recoveries related to loans repaid in 2025, partially offset by new and extended loans during 2024 and 2025.]

Rewritten

[removed: - an increase] [added: *•*a decrease] in casualty-related losses from Hurricane Milton [removed: during the fourth quarter of] [added: which occurred in] 2024; [removed: and]

Rewritten

- [removed: an increase] [added: a decrease] in income tax expense [removed: primarily as a result of an] [added: related to: (i)] income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January [removed: 2024.][added: 2024 and (ii) the income tax benefit from an other-than-temporary impairment charge on a lab unconsolidated joint venture;]

New in FY2025

Other than retrospective updates for changes to our reportable segments as more fully described in this Form 10-K, please refer to Part II, Item 7.

New in FY2025

- During the year ended December 31, 2025, we completed the Gateway Crossing acquisition where we acquired 100% of a lab building in South San Francisco, California for consideration paid, net of discounts and closing costs, of $295 million and a 50% interest in a joint venture that owns five lab buildings and one other property on the same campus (the “Gateway Crossing JV”) for consideration paid, net of discounts and closing costs, of $132 million.

New in FY2025

In January 2026, we acquired the remaining 50% interest in the Gateway Crossing JV for consideration paid, net of discounts and closing costs, of $132 million, bringing our equity ownership in these six buildings to 100%.

New in FY2025

- During the year ended December 31, 2025, we also acquired: (i) a portfolio of three outpatient medical buildings in New York for $17 million, (ii) a lab land parcel in Cambridge, Massachusetts for $20 million, (iii) nine suites within an outpatient medical building in Atlanta, Georgia for $7 million, and (iv) an outpatient medical land parcel in Huntsville, Alabama for $7 million, and (v) formed two outpatient medical development joint ventures.

New in FY2025

- During the year ended December 31, 2025, we sold: (i) one outpatient medical land parcel for $4 million, (ii) nine outpatient medical buildings for $160 million, and (iii) a portfolio of 16 outpatient medical buildings for $182 million.

New in FY2025

- In January 2026, we acquired the remaining 46.5% interest in the SWF SH JV for $312 million, bringing our ownership interest in the 19 senior housing properties to 100%.

New in FY2025

- In January 2026, we acquired one lab land parcel in Cambridge, Massachusetts for $25 million.

New in FY2025

- In January 2026, we sold four lab buildings subject to a purchase option for $68 million.

New in FY2025

- In February 2025, we issued $500 million aggregate principal amount of 5.38% senior unsecured notes due 2035.

New in FY2025

- In June 2025, we repaid $452 million aggregate principal amount of 4.00% senior unsecured notes at maturity.

New in FY2025

- In August 2025, we issued $500 million aggregate principal amount of 4.75% senior unsecured notes due 2033.

New in FY2025

- In January 2026, we made a $103 million early full repayment of mortgage debt secured by two life plan communities with original maturities in December 2026.

New in FY2025

*•*In February 2025, we made a preferred equity investment in a joint venture that holds a lab campus under development in San Diego, California (the “HQ Point Preferred Equity Investment”).

New in FY2025

This investment is entitled to a preferred return, and we had committed to fund up to a total investment of $50 million, all of which was funded as of December 31, 2025.

New in FY2025

*•*During the year ended December 31, 2025, we received full repayment of two seller financing loans receivable secured by senior housing assets with an aggregate principal balance of $106 million.

New in FY2025

- In December 2025, we confidentially submitted a draft registration statement on Form S-11 to the SEC relating to the proposed Janus Living Offering.

New in FY2025

Following the Janus Living Offering, Janus Living will be externally managed by a wholly owned indirect subsidiary of Healthpeak under the terms of a management agreement, and Healthpeak will retain a substantial majority equity interest in Janus Living, with new public shareholders owning the remaining interest.

New in FY2025

Based on the anticipated ownership share and terms of the management agreement, we expect to continue to consolidate Janus Living subsequent to the Offering.

New in FY2025

We expect to complete the Janus Living Offering in the first half of 2026, subject to market conditions, receipt of regulatory approvals, completion of related financings, completion of the SEC’s review, and other customary conditions.

New in FY2025

Our Board of Directors declares our common stock cash dividends on a quarterly basis.

New in FY2025

On January 4, 2026, our Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of January, February, and March 2026, payable on January 30, 2026, February 27, 2026, and March 31, 2026, respectively, to stockholders of record as of the close of business on January 16, 2026, February 13, 2026, and March 17, 2026, respectively.

New in FY2025

We evaluate our business and allocate resources among our operating segments: (i) outpatient medical, (ii) lab, (iii) senior housing, (iv) loans receivable, (v) a preferred equity investment, and (vi) three other properties, which are comprised of two properties previously included in our outpatient medical operating segment and one property acquired in connection with the Gateway Crossing acquisition.

New in FY2025

Our reportable segments, as determined in accordance with ASC 280, *Segment Reporting*, are as follows: (i) outpatient medical, (ii) lab, and (iii) senior housing.

New in FY2025

Transaction, merger, and restructuring-related costs include expenses incurred as a result of mergers, acquisitions, operator transitions, severance, and other investment pursuit costs.

New in FY2025

use of pro rata share information and its limitations.

New in FY2025

*•*other-than-temporary impairment charges on certain lab unconsolidated joint ventures in 2025;

New in FY2025

- a decrease in gain on sales of real estate related to fewer real estate dispositions in 2025;

New in FY2025

*•*an increase in noncontrolling interests’ share in earnings as a result of increased income from consolidated joint ventures acquired as part of the Merger;

New in FY2025

- an increase in income tax expense related to: (i) an increase in operating income associated with our life plan communities and (ii) the tax benefit from casualty-related losses recognized in 2024; and

New in FY2025

- an increase in Adjusted NOI generated from our senior housing segment related to: (i) increased rates for resident fees and (ii) higher occupancy;

New in FY2025

*•*a decrease in impairment charges associated with an asset impaired under the held for sale model that was recognized in 2024;

New in FY2025

- a decrease in loan loss reserves under the current expected credit losses model, which is primarily due to (i) reserves recognized in 2024 on loans receivable acquired as part of the Merger, (ii) changes in operating performance and fair values of the underlying collateral of the Company’s loans receivable and (iii) recoveries related to loans repaid in 2024 and 2025;

New in FY2025

*•*a decrease in interest expense related to: (i) the repayment of $348 million aggregate principal amount of 3.40% senior unsecured notes in February 2025 and (ii) the repayment of $452 million aggregate principal amount of 4.00% senior unsecured notes in June 2025; and

New in FY2025

- a decrease in general and administrative expenses due to: (i) lower compensation expense and (ii) merger-related synergies.

New in FY2025

- other-than-temporary impairment charges;

New in FY2025

For the year ended December 31, 2025, our Merger-Combined Same-Store consists of 597 properties representing properties fully operating on or prior to January 1, 2024 and that remained in operation through December 31, 2025.

New in FY2025

From our 2024 segment presentation in Part II, Item 7.

New in FY2025

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on February 4, 2025, 19 properties were added to the senior housing segment as a result of a change in the reportable segment.

New in FY2025

Additionally, we removed two properties that were reclassified from the outpatient medical segment to the other non-reportable segments.

New in FY2025

Also included in other non-reportable segments as of December 31, 2025 is one other property that was acquired as part of the Gateway Crossing acquisition, as described above, which has no impact on prior period information presented for the lab segment.

Dropped from FY2024

For a discussion of the year ended December 31, 2023 compared to the year ended December 31, 2022, please refer to Part II, Item 7.

Dropped from FY2024

While there have been signs that cost pressures are moderating, there can be no assurance that this will continue to be the case.

Dropped from FY2024

On March 1, 2024, we completed the Merger with Physicians Realty Trust, which resulted in the acquisition of 299 outpatient medical buildings.

Dropped from FY2024

- In April 2024, we exercised our option to buy out four redeemable noncontrolling interests, made aggregate cash payments for the total redemption value of $53 million to the related noncontrolling interest holders, and acquired the redeemable noncontrolling interests associated with these entities.

Dropped from FY2024

- In March 2024, we executed a $750 million five year unsecured term loan (the “2029 Term Loan”) as an incremental facility under the term loan agreement.

Dropped from FY2024

In January 2024, we entered into forward-starting interest rate swap instruments on the 2029 Term Loan which are designated as cash flow hedges and establish a blended fixed effective interest rate of 4.66%.

Dropped from FY2024

*•*During the year ended December 31, 2024, we refinanced one of our existing seller financing loans receivable, extended the maturity date to August 2027, and received aggregate partial principal repayments of $74 million.

Dropped from FY2024

*•*During the year ended December 31, 2024, we executed an early lease renewal for approximately 2 million square feet leased by CommonSpirit Health, which is subject to a master agreement, which extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%.

Dropped from FY2024

- In January 2025, we received full repayment of: (i) the $48 million outstanding balance of one of our seller financing loans receivable and (ii) the $15 million outstanding balance of one secured loan with an original maturity of July 2027.

Dropped from FY2024

The dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025.

Dropped from FY2024

We evaluate our business and allocate resources among our operating segments: (i) outpatient medical, (ii) lab, (iii) CCRC, (iv) an interest in our unconsolidated SWF SH JV, and (v) loans receivable.

Dropped from FY2024

Our operating segments are aggregated into the following reportable segments: (i) outpatient medical, (ii) lab, and (iii) CCRC.

Dropped from FY2024

ventures.

Dropped from FY2024

Transaction and merger-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities.

Dropped from FY2024

- impairments of depreciable real estate; and

Dropped from FY2024

| Rental and related revenues | | | $ | 1,197,264 | | | | | $ | 1,138,437 | | | | | $ | 58,827 | | | | | $ | 1,205,744 | | | | | $ | 753,479 | | | | | $ | 452,265 | |

Dropped from FY2024

| Healthpeak’s share of unconsolidated joint venture total revenues | | | 26,092 | | | | | | 24,091 | | | | | | 2,001 | | | | | | 24,041 | | | | | | 3,033 | | | | | | 21,008 | | |

Dropped from FY2024

| Noncontrolling interests’ share of consolidated joint venture total revenues | | | (36,083) | | | | | | (35,365) | | | | | | (718) | | | | | | (37,643) | | | | | | (35,073) | | | | | | (2,570) | | |

Dropped from FY2024

| Operating expenses | | | (395,079) | | | | | | (382,748) | | | | | | (12,331) | | | | | | (405,993) | | | | | | (263,132) | | | | | | (142,861) | | |

Dropped from FY2024

| Healthpeak’s share of unconsolidated joint venture operating expenses | | | (10,007) | | | | | | (8,986) | | | | | | (1,021) | | | | | | (9,034) | | | | | | (1,189) | | | | | | (7,845) | | |

Dropped from FY2024

| Adjustments to NOI(3) | | | (37,396) | | | | | | (14,468) | | | | | | (22,928) | | | | | | (38,967) | | | | | | (14,314) | | | | | | (24,653) | | |

Dropped from FY2024

| Adjusted NOI | | | $ | 754,862 | | | | | $ | 731,110 | | | | | $ | 23,752 | | | | | 748,730 | | | | | | 452,725 | | | | | | 296,005 | | |

Dropped from FY2024

| Merger-Combined SS Adjusted NOI | | | | | | | | | | | | | | | | | | | | | $ | 754,862 | | | | | $ | 731,110 | | | | | $ | 23,752 | |

Dropped from FY2024

| Average occupancy(6) | | | 92.3 | | % | | | | 92.1 | | % | | | | | | | | | | 92.1 | | % | | | | 90.1 | | % | | | | | | |

Dropped from FY2024

| Healthpeak’s share of unconsolidated joint venture total revenues | | | 3,229 | | | | | | 3,347 | | | | | | (118) | | | | | | 19,733 | | | | | | 9,924 | | | | | | 9,809 | | |

Dropped from FY2024

| Healthpeak’s share of unconsolidated joint venture operating expenses | | | (1,800) | | | | | | (1,878) | | | | | | 78 | | | | | | (6,366) | | | | | | (4,092) | | | | | | (2,274) | | |

Dropped from FY2024

| Noncontrolling interests’ share of consolidated joint venture operating expenses | | | — | | | | | | — | | | | | | — | | | | | | 52 | | | | | | 156 | | | | | | (104) | | |

Dropped from FY2024

Continuing Care Retirement Community

Dropped from FY2024

| Adjustments to NOI(2) | | | (3,122) | | | | | | (1,618) | | | | | | (1,504) | | | | | | (3,123) | | | | | | (1,618) | | | | | | (1,505) | | |

Dropped from FY2024

| Adjusted NOI | | | $ | 137,217 | | | | | $ | 113,612 | | | | | $ | 23,605 | | | | | 136,104 | | | | | | 112,511 | | | | | | 23,593 | | |

Dropped from FY2024

| Merger-Combined SS Adjusted NOI | | | | | | | | | | | | | | | | | | | | | $ | 137,217 | | | | | $ | 113,612 | | | | | $ | 23,605 | |

Dropped from FY2024

| Average occupancy(4) | | | 85.4 | | % | | | | 83.8 | | % | | | | | | | | | | 85.4 | | % | | | | 83.9 | | % | | | | | | |

Dropped from FY2024

(3)From our 2023 presentation of Same-Store, no properties were added or removed.

Dropped from FY2024

| Noncontrolling interests’ share in continuing operations | | | (24,161) | | | | | | (28,748) | | | | | | 4,587 | | |

Dropped from FY2024

Impairments and loan loss reserves (recoveries), net increased for the year ended December 31, 2024 primarily as a result of: (i) impairment charges associated with an asset impaired under the held for sale model and (ii) an increase in loan loss reserves under the current expected credit losses model, which is primarily due to reserves recognized on secured loans and mezzanine loans receivable acquired as part of the Merger.

Dropped from FY2024

Gain on sales of real estate, net increased during the year ended December 31, 2024 primarily as a result of the $179 million gain on sales from: (i) a portfolio of 61 outpatient medical buildings sold for proceeds of $697 million, (ii) 14 outpatient medical buildings sold for proceeds of $220 million, (iii) a portfolio of seven lab buildings sold for proceeds of $180 million, and (vi) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company’s CCRC campuses sold for proceeds of $12 million, which were sold during the year ended December 31, 2024, as compared to the $81 million gain on sales from: (i) two lab buildings in Durham, North Carolina sold for proceeds of $113 million and (ii) two outpatient medical buildings sold for proceeds of $32 million, which were sold during the year ended December 31, 2023.

Dropped from FY2024

Income tax expense increased for the year ended December 31, 2024 primarily as a result of: (i) income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024 and (ii) an increase in operating income associated with our CCRCs, partially offset by the tax impact of casualty-related losses from Hurricane Milton.

Dropped from FY2024

Noncontrolling interests’ share in continuing operations decreased for the year ended December 31, 2024 primarily as a result of a gain on sale of an outpatient medical building in a consolidated joint venture in the first quarter of 2023, partially offset by increased income from consolidated joint ventures acquired as part of the Merger.

Dropped from FY2024

As a result of the repayment of a secured loan in January 2025, this remaining commitment was reduced to $67 million.

Dropped from FY2024

Our noncontrolling interest holder has the ability to put their equity interest to us beginning in September 2025.

An excerpt. Shown here: 40 of 184 rewritten, 40 of 198 added and 40 of 75 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the FY2025 filing and the FY2024 filing.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

8 rewritten, 0 added, 1 removed, 14 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

At December 31, [removed: 2024,] [added: 2025,] a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to [removed: $53] [added: $38] million.

Rewritten

At December 31, [removed: 2024,] [added: 2025,] our exposure to interest rate risk was primarily on our variable rate debt.

Rewritten

At December 31, [removed: 2024,] [added: 2025,] we had the following swapped to fixed rates through interest rate swap instruments: (i) the $750 million 2029 Term Loan, (ii) the $500 million 2027 Term Loans, (iii) the $400 million 2028 Term Loan, and (iv) $142 million of variable rate mortgage debt.

Rewritten

At December 31, [removed: 2024,] [added: 2025,] both the fair value and carrying value of the interest rate swap [removed: instruments] [added: assets] were [removed: $35] [added: $6 million and both the fair value and carrying value of the interest rate swap liabilities were $10] million.

Rewritten

Our remaining variable rate debt at December 31, [removed: 2024] [added: 2025] was comprised of borrowings under our commercial paper program and certain of our mortgage debt.

Rewritten

At December 31, [removed: 2024,] [added: 2025,] a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately [removed: $241] [added: $269] million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately [removed: $259] [added: $288] million.

Rewritten

Additionally, at December 31, [removed: 2024,] [added: 2025,] a one percentage point increase or decrease in interest rates would change the fair value of our fixed rate loans receivable by [removed: approximately $15] [added: up to $13] million.

Rewritten

Assuming a one percentage point increase in the interest rates related to our variable rate debt, and assuming no other changes in the outstanding balance at December 31, [removed: 2024,] [added: 2025,] our annual interest expense would increase by approximately [removed: $3] [added: $12] million.

Dropped from FY2024

Lastly, assuming a one percentage point decrease in the interest rates related to our variable rate loans receivable, and assuming no other changes in the outstanding balance at December 31, 2024, our annual interest income would decrease by approximately $1 million.

Item 1. Business

41 rewritten, 21 added, 18 removed, 223 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and [removed: continuing care retirement community (“CCRC”)] [added: senior housing] real estate.

Rewritten

Under the [removed: CCRC] [added: senior housing] segment, our properties are operated through RIDEA structures.

Rewritten

At December 31, [removed: 2024,] [added: 2025,] our portfolio of investments, including properties in certain of our unconsolidated joint ventures, consisted of interests in [removed: 697] [added: 689] properties: (i) Outpatient medical – [removed: 524] [added: 507] properties; (ii) Lab – [removed: 139] [added: 145] properties; (iii) [removed: CCRC] [added: Senior housing] – [removed: 15] [added: 34] properties; and (iv) Other non-reportable – [removed: 19] [added: 3] properties.

Rewritten

The following table summarizes information for our reportable segments for the year ended December 31, [removed: 2024] [added: 2025] (dollars in thousands):

Rewritten

For a description of our significant activities during [removed: 2024,] [added: 2025,] see “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Company Highlights” in this report.

Rewritten

Our portfolio is [added: primarily] focused on outpatient medical and lab buildings, favorable sectors that benefit from the universal desire for improved [removed: health.][added: health, as well as life plan community and senior housing facilities, which benefit from favorable demographic trends.]

Rewritten

(iii)Our *partnerships*: We work with leading pharmaceutical, biotechnology, and medical device companies, as well as healthcare delivery systems, specialty physician groups, and other healthcare service [removed: providers,] [added: providers and senior housing operators and managers,] to meet their real estate needs.

Rewritten

Our outpatient medical buildings are typically multi-tenant properties leased to healthcare providers (hospitals and physician practices), with approximately [removed: 78%] [added: 79%] of our outpatient medical buildings located on or adjacent to hospital campuses and 96% affiliated with hospital systems as of December 31, [removed: 2024] [added: 2025] (based on total square feet).

Rewritten

At December 31, [removed: 2024,] [added: 2025,] approximately [removed: 76%] [added: 72%] of our outpatient medical buildings were triple-net leased (based on leased square feet) with the remaining leased under gross or modified gross leases.

Rewritten

The following table provides information about our most significant outpatient medical tenant concentration for the year ended December 31, [removed: 2024:][added: 2025:]

Rewritten

During the year ended December 31, [removed: 2024,] [added: 2025,] we had various other outpatient medical tenants that each represented 1% or less of total revenues.

Rewritten

Our properties are located in well-established geographical markets known for scientific research and drug discovery, including San [removed: Francisco (53%) and San Diego (17%), California, and] [added: Francisco, California (59%),] Boston, Massachusetts [removed: (28%)] [added: (22%), and San Diego, California (17%)] (based on total square feet).

Rewritten

At December 31, [removed: 2024, 88%] [added: 2025, 89%] of our lab properties were triple-net leased (based on leased square feet).

Rewritten

During the year ended December 31, [removed: 2024,] [added: 2025,] we had various lab tenants that each represented 1% or less of total revenues.

Rewritten

[removed: CCRCs] [added: Life plan communities] are retirement communities that include independent living, assisted living, memory care, and skilled nursing units to provide a continuum of care in an integrated campus.

Rewritten

Our [removed: CCRCs] [added: life plan communities] are owned through RIDEA structures, which is permitted by the Housing and Economic Recovery Act of 2008, and includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007.

Rewritten

The management agreements we have in RIDEA structures related to [removed: CCRCs] [added: life plan communities] have original terms ranging from 10 to 15 years, with mutual renewal options.

Rewritten

[removed: CCRCs are different] [added: Life plan communities differ] from other housing and care options for seniors because they typically provide written agreements or long-term contracts between residents and the communities (frequently lasting the term of the resident’s lifetime), which offer a continuum of housing, services, and healthcare on one campus or site.

Rewritten

[removed: CCRCs] [added: Life plan communities] are appealing as they allow residents to “age in place” and typically the individual is independent and in relatively good health upon entry.

Rewritten

*Other non-reportable [removed: segment*][added: segments*]

Rewritten

The properties in our SWF SH JV are [added: also] owned through RIDEA structures and include independent living facilities and assisted living facilities, which cater to different segments of the elderly population based upon their personal needs.

Rewritten

Increased competition and resulting capitalization rate compression, as well as the impacts of [removed: inflation and higher] [added: elevated] interest rates, make it more challenging for us to identify and successfully capitalize on opportunities that meet our objectives.

Rewritten

[removed: Where we have used a RIDEA structure,] [added: In our senior housing segment,] we are dependent on management companies to fulfill our compliance obligations, and we have developed a program to periodically monitor compliance with such obligations.

Rewritten

The Centers for Medicare and Medicaid Services (“CMS”) defines the [removed: new] disclosable parties to include members of the facility’s governing body, persons, or entities who are an officer, director, member, partner, trustee, or managing employee of the facility, persons, or entities that exercise operational, financial, or managerial control, lease or sublease real property to the facility, own a direct or indirect interest of five percent or greater of the real property, or provide management or administrative services to the facility.

Rewritten

This [removed: new] disclosure requirement involves reporting extensive information and may complicate our healthcare facility operators’ efforts to comply with Medicare and Medicaid requirements.

Rewritten

Failure to comply with the [removed: new] disclosure requirements could negatively affect our healthcare facility operators’ participation in Medicare and state Medicaid programs.

Rewritten

Our [removed: CCRCs] [added: life plan communities] are operated as entrance fee communities.

Rewritten

We maintain separate general and professional liability insurance for our [removed: CCRCs and the] senior housing [removed: facilities owned by our SWF SH JV.][added: properties.]

Rewritten

We periodically review whether we or our RIDEA operators will bear responsibility for maintaining the required insurance coverage for the applicable [removed: CCRCs and] senior housing [removed: facilities owned by our SWF SH JV,] [added: properties,] but the costs of such insurance are facility expenses paid from the revenues of those properties, regardless of who maintains the insurance.

Rewritten

We believe that corporate impact initiatives are [removed: a vital] part of [added: our] corporate responsibility, which supports our primary goal of increasing stockholder value through profitable growth.

Rewritten

We use an integrated approach to corporate impact throughout our business to identify risks and opportunities, capture efficiencies and cost savings, and report on the issues [removed: most] relevant to stakeholders.

Rewritten

*Environment:* Our environmental management [removed: programs strive] [added: program strives] to make our buildings more sustainable and capture cost efficiencies that ultimately benefit our investors, [removed: employees,] tenants, business partners, and other stakeholders, while reducing our carbon footprint and providing a positive impact on the communities in which we operate.

Rewritten

We regularly assess the [added: climate-related] risks and financial impacts to our [removed: business posed by climate change,] [added: business,] including transition risks, physical climate risks, potential business disruption, and regulatory requirements, and work with our property managers, operators, and tenants to implement projects to mitigate these risks and impacts.

Rewritten

- Obtained 6 new LEED certifications, [removed: 19] [added: 14] new ENERGY STAR certifications, [added: 135 ENERGY STAR recertifications,] and [removed: 150] [added: 13] ENERGY STAR [removed: recertifications] [added: NextGen certifications] in [removed: 2024][added: 2025]

Rewritten

- Received a Green Star rating from the Global Real Estate Sustainability Benchmark (“GRESB”) for the [removed: thirteenth] [added: fourteenth] consecutive year, recognizing leading sustainability performance in our sector

Rewritten

- Named to *Newsweek*’s America’s Most Responsible Companies list for the [removed: sixth] [added: seventh] consecutive year

Rewritten

- Named to the S&P Global Sustainability Yearbook for the [removed: ninth] [added: tenth] consecutive year

Rewritten

For additional information regarding our corporate impact initiatives, methodologies, and [removed: approach to climate change,] [added: strategy,] please visit our website at www.healthpeak.com/corporate-impact.

Rewritten

Our employees represent our greatest asset, and as of December 31, [removed: 2024,] [added: 2025,] we had [removed: 387] [added: 411] full-time employees.

Rewritten

Our Board of Directors, through its Compensation and Human Capital Committee, retains oversight of human capital management, including corporate culture, [removed: diversity, inclusion,] talent acquisition, retention, employee satisfaction, engagement, and succession planning.

New in FY2025

We are organized as an umbrella partnership REIT (“UPREIT”).

New in FY2025

We have other non-reportable segments that are comprised primarily of: (i) loans receivable, (ii) a preferred equity investment, and (iii) three other properties.

New in FY2025

On March 1, 2024 (the “Closing Date”), we completed our merger with Physicians Realty Trust (the “Merger”).

New in FY2025

In December 2025, we confidentially submitted a draft registration statement on Form S-11 to the SEC relating to the proposed initial public offering (the “Offering” or “Janus Living Offering”) of shares of common stock of a newly formed company, Janus Living, Inc. (“Janus Living”), which will be dedicated to senior housing and which intends to elect and qualify to be taxed as a REIT.

New in FY2025

We will contribute our 34-community, 10,422-unit senior housing portfolio to Janus Living in exchange for a majority ownership interest in Janus Living.

New in FY2025

Immediately following the Janus Living Offering, we will serve as its external manager and we intend to retain a substantial majority interest in Janus Living, with new public shareholders owning the remaining interest.

New in FY2025

Based on the anticipated ownership share and terms of the management agreement, we expect to continue to consolidate Janus Living subsequent to the Offering.

New in FY2025

We expect to complete the Offering in the first half of 2026, subject to market conditions, receipt of regulatory approvals, completion of related financings, completion of the SEC’s review, and other customary conditions.

New in FY2025

During the fourth quarter of 2025, in connection with the planned Offering of Janus Living, our chief operating decision maker (“CODM”), the President and Chief Executive Officer (“CEO”), began evaluating our life plan communities (formerly known as continuing care retirement communities, or CCRCs) and our unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing properties (our “SWF SH JV”) as a single operating and reportable segment, referred to as senior housing.

New in FY2025

Also during the fourth quarter of 2025, two other properties were reclassified from the outpatient medical segment to the other non-reportable segments as these properties are not representative of the characteristics of the outpatient medical segment and therefore, are no longer evaluated by the CODM in conjunction with the outpatient medical properties.

New in FY2025

Also included in other non-reportable segments as of December 31, 2025 is one other property that was acquired as part of the Gateway Crossing acquisition, as described below.

New in FY2025

Accordingly, all prior period segment information has been recast to conform to the current period presentation.

New in FY2025

| Outpatient medical | | | | | | $ | 795,843 | |

New in FY2025

| Lab | | | | | | 567,358 | | |

New in FY2025

| Senior housing | | | | | | 176,741 | | |

New in FY2025

In addition, as discussed above, following the Janus Living Offering, Janus Living will be externally managed by our wholly owned indirect subsidiary under the terms of a management agreement, and we will retain a substantial majority equity interest in Janus Living.

New in FY2025

*Senior Housing*

New in FY2025

Our senior housing segment includes life plan communities and our SWF SH JV, an interest in an unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets.

New in FY2025

In January 2026, we acquired the remaining 46.5% interest in the SWF SH JV, bringing our ownership interest in these 19 senior housing properties to 100%.

New in FY2025

At December 31, 2025, we had the following investments in our other non-reportable segments: (i) loans receivable, (ii) a preferred equity investment, and (iii) three other properties that are not representative of the characteristics of the outpatient medical and lab reportable segments discussed above.

New in FY2025

If a lab tenant fails to obtain or experiences significant delays in obtaining such approvals, it may have a significant effect on the tenant’s operations and financial condition, which in turn may adversely impact us, as detailed below and set forth under “Item 1A, Risk Factors” in this report.

Dropped from FY2024

In 2023, we completed our corporate reorganization (the “Reorganization”) into an umbrella partnership REIT (“UPREIT”).

Dropped from FY2024

We have other non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (our “SWF SH JV”) and (ii) loans receivable.

Dropped from FY2024

*The Merger*

Dropped from FY2024

On March 1, 2024 (the “Closing Date”), pursuant to the Agreement and Plan of Merger dated October 29, 2023 (the “Merger Agreement”), by and among us, DOC DR Holdco, LLC, one of our wholly owned subsidiaries (“DOC DR Holdco”), DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (“DOC DR OP Sub”), Physicians Realty Trust, Physicians Realty L.P. (the “Physicians Partnership”): (i) Physicians Realty Trust merged with and into DOC DR Holdco (the “Company Merger”), with DOC DR Holdco surviving as our wholly owned subsidiary (the “Company Surviving Entity”); (ii) immediately following the effectiveness of the Company Merger, we contributed all of the outstanding equity interests in the Company Surviving Entity to Healthpeak OP (the “Contribution”); and (iii) immediately following the Contribution, Physicians Partnership merged with and into DOC DR OP Sub (the “Partnership Merger” and, together with the Company Merger, the “Merger”), with DOC DR OP Sub surviving as a subsidiary of Healthpeak OP.

Dropped from FY2024

On the Closing Date, each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares that were canceled in accordance with the Merger Agreement) were converted into the right to receive 0.674 (the “Exchange Ratio”) shares of our common stock, and each outstanding common unit of the Physicians Partnership was converted into common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.

Dropped from FY2024

| Outpatient medical | | | | | | $ | 748,730 | |

Dropped from FY2024

| Lab | | | | | | 590,606 | | |

Dropped from FY2024

| CCRC | | | | | | 136,104 | | |

Dropped from FY2024

*Continuing care retirement community, or CCRC*

Dropped from FY2024

We are substantially limited in our ability to control or influence day-to-day operations under a RIDEA structure, and thus rely on the third-party operator to manage and operate the business.

Dropped from FY2024

At December 31, 2024, we had the following investments in our other non-reportable segments: (i) our unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets (which we refer to as our SWF SH JV) and (ii) loans receivable.

Dropped from FY2024

- Reported a reduction of 2.1% in Scope 1 and Scope 2 greenhouse gas emissions (“GHG”) in 2023 compared to 2022 on a like-for-like comparative basis (as defined below)

Dropped from FY2024

- Named an ENERGY STAR Partner of the Year for Sustained Excellence in 2024, marking our fourth time receiving the Partner of the Year award and first time being recognized for Sustained Excellence

Dropped from FY2024

- Named a constituent in the FTSE4Good Index for the thirteenth consecutive year

Dropped from FY2024

- Named a constituent in the S&P Global Dow Jones Sustainability World Index for the fifth time and S&P Global North America Dow Jones Sustainability Index for the twelfth consecutive year

Dropped from FY2024

*•*Workforce Diversity: We believe we are a stronger organization when our workforce represents a diversity of ideas and experiences.

Dropped from FY2024

We value and embrace such diversity in our employee recruiting, hiring, and development practices.

Dropped from FY2024

Our workforce was made up of 59% female employees and 35% racially or ethnically diverse employees as of December 31, 2024.

An excerpt. Shown here: 40 of 41 rewritten, all 21 added and all 18 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2025 filing and the FY2024 filing.

Cover and table of contents

40 rewritten, 8 added, 7 removed, 110 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

For the fiscal year ended December 31, [removed: 2024][added: 2025]

Rewritten

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: [removed: $11.8] [added: $9.4] billion.

Rewritten

As of January [removed: 31, 2025,] [added: 30, 2026,] there were [removed: 699,564,637] [added: 695,043,997] shares of the registrant’s $1.00 par value common stock outstanding.

Rewritten

Portions of the definitive Proxy Statement for the registrant’s [removed: 2025] [added: 2026] Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission no later than 120 days after December 31, [removed: 2024,] [added: 2025,] have been incorporated by reference into Part III of this Report.

Rewritten

For the Fiscal Year Ended December 31, [removed: 2024][added: 2025]

Rewritten

| [Cautionary Language Regarding Forward-Looking [removed: Statements](#id87c1e19981e404fb2b458e86ff35366_10)] [added: Statements](#i9f4d17dc3a4a44b6ac4ecd42a230a144_10)] | | | | | | [removed: [1](#id87c1e19981e404fb2b458e86ff35366_10)] [added: [1](#i9f4d17dc3a4a44b6ac4ecd42a230a144_10)] | | |

Rewritten

| [Risk Factors [removed: Summary](#id87c1e19981e404fb2b458e86ff35366_13)] [added: Summary](#i9f4d17dc3a4a44b6ac4ecd42a230a144_13)] | | | | | | [removed: [1](#id87c1e19981e404fb2b458e86ff35366_13)] [added: [1](#i9f4d17dc3a4a44b6ac4ecd42a230a144_13)] | | |

Rewritten

| [Important Information Regarding Our Disclosure to [removed: Investors](#id87c1e19981e404fb2b458e86ff35366_16)] [added: Investors](#i9f4d17dc3a4a44b6ac4ecd42a230a144_16)] | | | | | | [removed: [3](#id87c1e19981e404fb2b458e86ff35366_16)] [added: [3](#i9f4d17dc3a4a44b6ac4ecd42a230a144_16)] | | |

Rewritten

| [Item [removed: 1.](#id87c1e19981e404fb2b458e86ff35366_22)] [added: 1.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_22)] | | | [removed: [Business](#id87c1e19981e404fb2b458e86ff35366_22)] [added: [Business](#i9f4d17dc3a4a44b6ac4ecd42a230a144_22)] | | | [removed: [4](#id87c1e19981e404fb2b458e86ff35366_22)] [added: [4](#i9f4d17dc3a4a44b6ac4ecd42a230a144_22)] | | |

Rewritten

| [Item [removed: 1A.](#id87c1e19981e404fb2b458e86ff35366_25)] [added: 1A.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_25)] | | | [Risk [removed: Factors](#id87c1e19981e404fb2b458e86ff35366_25)] [added: Factors](#i9f4d17dc3a4a44b6ac4ecd42a230a144_25)] | | | [removed: [14](#id87c1e19981e404fb2b458e86ff35366_25)] [added: [14](#i9f4d17dc3a4a44b6ac4ecd42a230a144_25)] | | |

Rewritten

| [Item [removed: 1B.](#id87c1e19981e404fb2b458e86ff35366_28)] [added: 1B.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_28)] | | | [Unresolved Staff [removed: Comments](#id87c1e19981e404fb2b458e86ff35366_28)] [added: Comments](#i9f4d17dc3a4a44b6ac4ecd42a230a144_28)] | | | [removed: [38](#id87c1e19981e404fb2b458e86ff35366_28)] [added: [39](#i9f4d17dc3a4a44b6ac4ecd42a230a144_28)] | | |

Rewritten

| [Item [removed: 1C.](#id87c1e19981e404fb2b458e86ff35366_31)] [added: 1C.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_31)] | | | [removed: [Cybersecurity](#id87c1e19981e404fb2b458e86ff35366_31)] [added: [Cybersecurity](#i9f4d17dc3a4a44b6ac4ecd42a230a144_31)] | | | [removed: [38](#id87c1e19981e404fb2b458e86ff35366_31)] [added: [39](#i9f4d17dc3a4a44b6ac4ecd42a230a144_31)] | | |

Rewritten

| [Item [removed: 2.](#id87c1e19981e404fb2b458e86ff35366_34)] [added: 2.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_34)] | | | [removed: [Properties](#id87c1e19981e404fb2b458e86ff35366_34)] [added: [Properties](#i9f4d17dc3a4a44b6ac4ecd42a230a144_34)] | | | [removed: [39](#id87c1e19981e404fb2b458e86ff35366_34)] [added: [40](#i9f4d17dc3a4a44b6ac4ecd42a230a144_34)] | | |

Rewritten

| [Item [removed: 3.](#id87c1e19981e404fb2b458e86ff35366_37)] [added: 3.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_37)] | | | [Legal [removed: Proceedings](#id87c1e19981e404fb2b458e86ff35366_37)] [added: Proceedings](#i9f4d17dc3a4a44b6ac4ecd42a230a144_37)] | | | [removed: [42](#id87c1e19981e404fb2b458e86ff35366_37)] [added: [44](#i9f4d17dc3a4a44b6ac4ecd42a230a144_37)] | | |

Rewritten

| [Item [removed: 4.](#id87c1e19981e404fb2b458e86ff35366_40)] [added: 4.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_40)] | | | [Mine Safety [removed: Disclosures](#id87c1e19981e404fb2b458e86ff35366_40)] [added: Disclosures](#i9f4d17dc3a4a44b6ac4ecd42a230a144_40)] | | | [removed: [42](#id87c1e19981e404fb2b458e86ff35366_40)] [added: [44](#i9f4d17dc3a4a44b6ac4ecd42a230a144_40)] | | |

Rewritten

| [Item [removed: 5.](#id87c1e19981e404fb2b458e86ff35366_46)] [added: 5.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_46)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#id87c1e19981e404fb2b458e86ff35366_46)] [added: Securities](#i9f4d17dc3a4a44b6ac4ecd42a230a144_46)] | | | [removed: [43](#id87c1e19981e404fb2b458e86ff35366_46)] [added: [45](#i9f4d17dc3a4a44b6ac4ecd42a230a144_46)] | | |

Rewritten

| [Item [removed: 6.](#id87c1e19981e404fb2b458e86ff35366_49)] [added: 6.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_49)] | | | [removed: [\[Reserved\]](#id87c1e19981e404fb2b458e86ff35366_49)] [added: [\[Reserved\]](#i9f4d17dc3a4a44b6ac4ecd42a230a144_49)] | | | [removed: [46](#id87c1e19981e404fb2b458e86ff35366_49)] [added: [47](#i9f4d17dc3a4a44b6ac4ecd42a230a144_49)] | | |

Rewritten

| [Item [removed: 7.](#id87c1e19981e404fb2b458e86ff35366_52)] [added: 7.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_52)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#id87c1e19981e404fb2b458e86ff35366_52)] [added: Operations](#i9f4d17dc3a4a44b6ac4ecd42a230a144_52)] | | | [removed: [46](#id87c1e19981e404fb2b458e86ff35366_52)] [added: [47](#i9f4d17dc3a4a44b6ac4ecd42a230a144_52)] | | |

Rewritten

| [Item [removed: 7A.](#id87c1e19981e404fb2b458e86ff35366_100)] [added: 7A.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_100)] | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#id87c1e19981e404fb2b458e86ff35366_100)] [added: Risk](#i9f4d17dc3a4a44b6ac4ecd42a230a144_100)] | | | [removed: [65](#id87c1e19981e404fb2b458e86ff35366_100)] [added: [71](#i9f4d17dc3a4a44b6ac4ecd42a230a144_100)] | | |

Rewritten

| [Item [removed: 8.](#id87c1e19981e404fb2b458e86ff35366_103)] [added: 8.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_103)] | | | [Financial Statements and Supplementary [removed: Data](#id87c1e19981e404fb2b458e86ff35366_103)] [added: Data](#i9f4d17dc3a4a44b6ac4ecd42a230a144_103)] | | | [removed: [67](#id87c1e19981e404fb2b458e86ff35366_103)] [added: [72](#i9f4d17dc3a4a44b6ac4ecd42a230a144_103)] | | |

Rewritten

| [Item [removed: 9.](#id87c1e19981e404fb2b458e86ff35366_217)] [added: 9.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_217)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#id87c1e19981e404fb2b458e86ff35366_217)] [added: Disclosure](#i9f4d17dc3a4a44b6ac4ecd42a230a144_217)] | | | [removed: [142](#id87c1e19981e404fb2b458e86ff35366_217)] [added: [146](#i9f4d17dc3a4a44b6ac4ecd42a230a144_217)] | | |

Rewritten

| [Item [removed: 9A.](#id87c1e19981e404fb2b458e86ff35366_220)] [added: 9A.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_220)] | | | [Controls and [removed: Procedures](#id87c1e19981e404fb2b458e86ff35366_220)] [added: Procedures](#i9f4d17dc3a4a44b6ac4ecd42a230a144_220)] | | | [removed: [142](#id87c1e19981e404fb2b458e86ff35366_220)] [added: [146](#i9f4d17dc3a4a44b6ac4ecd42a230a144_220)] | | |

Rewritten

| [Item [removed: 9B.](#id87c1e19981e404fb2b458e86ff35366_226)] [added: 9B.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_226)] | | | [Other [removed: Information](#id87c1e19981e404fb2b458e86ff35366_226)] [added: Information](#i9f4d17dc3a4a44b6ac4ecd42a230a144_226)] | | | [removed: [144](#id87c1e19981e404fb2b458e86ff35366_226)] [added: [148](#i9f4d17dc3a4a44b6ac4ecd42a230a144_226)] | | |

Rewritten

| [Item [removed: 9C.](#id87c1e19981e404fb2b458e86ff35366_229)] [added: 9C.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_229)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#id87c1e19981e404fb2b458e86ff35366_229)] [added: Inspections](#i9f4d17dc3a4a44b6ac4ecd42a230a144_229)] | | | [removed: [144](#id87c1e19981e404fb2b458e86ff35366_229)] [added: [148](#i9f4d17dc3a4a44b6ac4ecd42a230a144_229)] | | |

Rewritten

| [Part [removed: III](#id87c1e19981e404fb2b458e86ff35366_232)] [added: III](#i9f4d17dc3a4a44b6ac4ecd42a230a144_232)] | | | | | | [removed: [145](#id87c1e19981e404fb2b458e86ff35366_232)] [added: [149](#i9f4d17dc3a4a44b6ac4ecd42a230a144_232)] | | |

Rewritten

| [Item [removed: 10.](#id87c1e19981e404fb2b458e86ff35366_235)] [added: 10.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_235)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#id87c1e19981e404fb2b458e86ff35366_235)] [added: Governance](#i9f4d17dc3a4a44b6ac4ecd42a230a144_235)] | | | [removed: [145](#id87c1e19981e404fb2b458e86ff35366_235)] [added: [149](#i9f4d17dc3a4a44b6ac4ecd42a230a144_235)] | | |

Rewritten

| [Item [removed: 11.](#id87c1e19981e404fb2b458e86ff35366_238)] [added: 11.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_238)] | | | [Executive [removed: Compensation](#id87c1e19981e404fb2b458e86ff35366_238)] [added: Compensation](#i9f4d17dc3a4a44b6ac4ecd42a230a144_238)] | | | [removed: [145](#id87c1e19981e404fb2b458e86ff35366_238)] [added: [149](#i9f4d17dc3a4a44b6ac4ecd42a230a144_238)] | | |

Rewritten

| [Item [removed: 12.](#id87c1e19981e404fb2b458e86ff35366_241)] [added: 12.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_241)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#id87c1e19981e404fb2b458e86ff35366_241)] [added: Matters](#i9f4d17dc3a4a44b6ac4ecd42a230a144_241)] | | | [removed: [145](#id87c1e19981e404fb2b458e86ff35366_241)] [added: [149](#i9f4d17dc3a4a44b6ac4ecd42a230a144_241)] | | |

Rewritten

| [Item [removed: 13.](#id87c1e19981e404fb2b458e86ff35366_244)] [added: 13.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_244)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#id87c1e19981e404fb2b458e86ff35366_244)] [added: Independence](#i9f4d17dc3a4a44b6ac4ecd42a230a144_244)] | | | [removed: [145](#id87c1e19981e404fb2b458e86ff35366_244)] [added: [149](#i9f4d17dc3a4a44b6ac4ecd42a230a144_244)] | | |

Rewritten

| [Item [removed: 14.](#id87c1e19981e404fb2b458e86ff35366_247)] [added: 14.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_247)] | | | [Principal Accountant Fees and [removed: Services](#id87c1e19981e404fb2b458e86ff35366_247)] [added: Services](#i9f4d17dc3a4a44b6ac4ecd42a230a144_247)] | | | [removed: [145](#id87c1e19981e404fb2b458e86ff35366_247)] [added: [149](#i9f4d17dc3a4a44b6ac4ecd42a230a144_247)] | | |

Rewritten

| [Item [removed: 15.](#id87c1e19981e404fb2b458e86ff35366_253)] [added: 15.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_253)] | | | [Exhibits and Financial Statement [removed: Schedules](#id87c1e19981e404fb2b458e86ff35366_253)] [added: Schedules](#i9f4d17dc3a4a44b6ac4ecd42a230a144_253)] | | | [removed: [146](#id87c1e19981e404fb2b458e86ff35366_253)] [added: [150](#i9f4d17dc3a4a44b6ac4ecd42a230a144_253)] | | |

Rewritten

| [Item [removed: 16.](#id87c1e19981e404fb2b458e86ff35366_259)] [added: 16.](#i9f4d17dc3a4a44b6ac4ecd42a230a144_259)] | | | [Form 10-K [removed: Summary](#id87c1e19981e404fb2b458e86ff35366_259)] [added: Summary](#i9f4d17dc3a4a44b6ac4ecd42a230a144_259)] | | | [removed: [151](#id87c1e19981e404fb2b458e86ff35366_259)] [added: [156](#i9f4d17dc3a4a44b6ac4ecd42a230a144_259)] | | |

Rewritten

Statements in this Annual Report on Form 10-K that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as [removed: amended,] [added: amended (the “Securities Act”),] and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Rewritten

- macroeconomic trends that may increase [added: borrowing,] construction, labor, and other operating costs;

Rewritten

- environmental, social, and governance (“corporate impact”) and sustainability commitments and [added: changing] requirements, as well as stakeholder expectations;

Rewritten

- epidemics, pandemics, or other infectious diseases, [removed: including the coronavirus disease (“Covid”),] and health and safety measures intended to reduce their spread;

Rewritten

- increased [added: interest rates and] borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities;

Rewritten

- the requirements of, or changes to, governmental reimbursement programs such as Medicare or [removed: Medicaid, and legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services;][added: Medicaid;]

Rewritten

- our [added: past] participation in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) Provider Relief Fund and other Covid-related stimulus and relief programs;

Rewritten

The information disclosed through those channels may be considered to be material, so investors should monitor them in addition to our press releases, [removed: SEC] [added: Securities and Exchange Commission (“SEC”)] filings, and public conference calls and webcasts.

New in FY2025

| [Part I](#i9f4d17dc3a4a44b6ac4ecd42a230a144_19) | | | | | | [4](#i9f4d17dc3a4a44b6ac4ecd42a230a144_19) | | |

New in FY2025

| [Part II](#i9f4d17dc3a4a44b6ac4ecd42a230a144_43) | | | | | | [45](#i9f4d17dc3a4a44b6ac4ecd42a230a144_43) | | |

New in FY2025

| [Part IV](#i9f4d17dc3a4a44b6ac4ecd42a230a144_250) | | | | | | [150](#i9f4d17dc3a4a44b6ac4ecd42a230a144_250) | | |

New in FY2025

| | | | [Signatures](#i9f4d17dc3a4a44b6ac4ecd42a230a144_262) | | | [157](#i9f4d17dc3a4a44b6ac4ecd42a230a144_262) | | |

New in FY2025

- changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political administration;

New in FY2025

- the pending Janus Living Offering (as defined below) may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits;

New in FY2025

- our economic exposure to shifts in the price of Janus Living common stock and our ability to control the assets and activities of Janus Living;

New in FY2025

- potential conflicts of interest in our relationship with Janus Living;

Dropped from FY2024

| [Part I](#id87c1e19981e404fb2b458e86ff35366_19) | | | | | | [4](#id87c1e19981e404fb2b458e86ff35366_19) | | |

Dropped from FY2024

| [Part II](#id87c1e19981e404fb2b458e86ff35366_43) | | | | | | [43](#id87c1e19981e404fb2b458e86ff35366_43) | | |

Dropped from FY2024

| [Part IV](#id87c1e19981e404fb2b458e86ff35366_250) | | | | | | [146](#id87c1e19981e404fb2b458e86ff35366_250) | | |

Dropped from FY2024

| | | | [Signatures](#id87c1e19981e404fb2b458e86ff35366_262) | | | [152](#id87c1e19981e404fb2b458e86ff35366_262) | | |

Dropped from FY2024

- our ability to develop, maintain, or expand hospital and health system client relationships;

Dropped from FY2024

- changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate;

Dropped from FY2024

- our ability to successfully integrate our operations with Physicians Realty Trust and realize the anticipated synergies of the Merger (as defined below) and benefits of property management internalization;

Item 1C. Cybersecurity

1 rewritten, 0 added, 0 removed, 27 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

We have not identified risks from known cybersecurity threats within the prior [added: three] fiscal [removed: year,] [added: years,] including as a result of any prior cybersecurity incident, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.

Item 2. Properties

19 rewritten, 34 added, 24 removed, 43 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

The following table summarizes our consolidated property investments as of and for the year ended December 31, [removed: 2024] [added: 2025] (square feet and dollars in thousands):

Rewritten

(2)Represents gross real estate which includes the carrying amount of real estate after adding back accumulated [removed: depreciation and amortization.][added: depreciation.]

Rewritten

Excludes gross real estate of [removed: $11] [added: $158] million related to [removed: one] [added: six lab buildings and two] outpatient medical [removed: building] [added: buildings] classified as held for sale.

Rewritten

| | | | [removed: 2024] [added: 2025] | | | | | | [removed: 2023] [added: 2024] | | | | | | [removed: 2022] [added: 2023] | | | | | | | | | | | | | | |

Rewritten

| Average occupancy percentage(1) | | | 92 | | % | | | | [removed: 90] [added: 92] | | % | | | | 90 | | % | | | | | | | | | | | | |

Rewritten

| Average annual rent per square foot(2) | | | $ | [removed: 36] [added: 38] | | | | | $ | [removed: 35] [added: 36] | | | | | $ | [removed: 33] [added: 34] | | | | | | | | | | | | | |

Rewritten

| Average occupied square feet | | | [removed: 32,431] [added: 32,396] | | | | | | [removed: 21,337] [added: 31,767] | | | | | | [removed: 21,472] [added: 20,772] | | | | | | | | | | | | | | |

Rewritten

| Average occupancy percentage(1) | | | [removed: 96] [added: 95] | | % | | | | [removed: 98] [added: 96] | | % | | | | 98 | | % | | | | | | | | | | | | |

Rewritten

| Average annual rent per square foot(2) | | | $ | [removed: 87] [added: 90] | | | | | $ | [removed: 82] [added: 87] | | | | | $ | [removed: 71] [added: 82] | | | | | | | | | | | | | |

Rewritten

| Average occupied square feet | | | [removed: 9,404] [added: 8,860] | | | | | | [removed: 10,334] [added: 9,404] | | | | | | [removed: 10,610] [added: 10,334] | | | | | | | | | | | | | | |

Rewritten

| Average occupancy percentage(1) | | | [removed: 85] [added: 87] | | % | | | | [removed: 84] [added: 85] | | % | | | | [removed: 82] [added: 84] | | % | | | | | | | | | | | | |

Rewritten

| Average annual rent per occupied unit(3) | | | $ | [removed: 94,103] [added: 98,776] | | | | | $ | [removed: 88,524] [added: 94,103] | | | | | $ | [removed: 84,664] [added: 88,524] | | | | | | | | | | | | | |

Rewritten

| Average occupied units | | | [removed: 6,041] [added: 6,115] | | | | | | [removed: 5,960] [added: 6,041] | | | | | | [removed: 5,926] [added: 5,960] | | | | | | | | | | | | | | |

Rewritten

Average annual rent excludes termination fees and non-cash revenue adjustments (i.e., straight-line [removed: rents and] [added: rents,] amortization of market lease [removed: intangibles).][added: intangibles, and deferred revenues).]

Rewritten

The following table shows tenant lease expirations for the next 10 years and thereafter at our consolidated properties, assuming that none of the tenants exercise any of their renewal or purchase options, and excludes properties in our [removed: CCRC] [added: senior housing] segment and assets held for sale as of December 31, [removed: 2024] [added: 2025] (dollars and square feet in thousands):

Rewritten

| Segment | | | | | | Total | | | | | | [removed: 2025(1) | | | | | | 2026] [added: 2026(1)] | | | | | | 2027 | | | | | | 2028 | | | | | | 2029 | | | | | | 2030 | | | | | | 2031 | | | | | | [removed: 2032] [added: 3032] | | | | | | 2033 | | | | | | 2034 | | | | | | [added: 2035 | | | | | |] Thereafter | | |

Rewritten

| % of segment base rent | | | | | | 100 | | | | | | 12 | | | | | | [removed: 13] [added: 10] | | | | | | [removed: 10] [added: 12] | | | | | | 11 | | | | | | [removed: 11] [added: 10] | | | | | | [removed: 7] [added: 9] | | | | | | [removed: 7] [added: 8] | | | | | | [removed: 7] [added: 5] | | | | | | [removed: 6] [added: 5] | | | | | | 4 | | | | | | [removed: 12] [added: 14] | | |

Rewritten

| % of segment base rent | | | | | | 100 | | | | | | 6 | | | | | | [removed: 5] [added: 8] | | | | | | [removed: 10] [added: 5] | | | | | | [removed: 7] [added: 9] | | | | | | [removed: 9] [added: 14] | | | | | | 14 | | | | | | [removed: 12] [added: 10] | | | | | | [removed: 11] [added: 7] | | | | | | [removed: 8] [added: 12] | | | | | | [removed: 9] [added: 6] | | | | | | 9 | | |

Rewritten

| % of total base rent | | | | | | 100 | | | | | | [removed: 10] [added: 9] | | | | | | [removed: 10] [added: 9] | | | | | | [removed: 10] [added: 9] | | | | | | [removed: 9] [added: 10] | | | | | | [removed: 10] [added: 12] | | | | | | [removed: 10] [added: 11] | | | | | | 9 | | | | | | [removed: 9] [added: 6] | | | | | | [removed: 7] [added: 8] | | | | | | [removed: 6] [added: 5] | | | | | | [removed: 10] [added: 12] | | |

New in FY2025

| Texas | | | | | | 94 | | | | | | 9,067 | | | | | | $ | 2,040,402 | | | | | $ | 323,402 | | | | | $ | (111,949) | |

New in FY2025

| Florida | | | | | | 35 | | | | | | 2,027 | | | | | | 540,870 | | | | | | 80,411 | | | | | | (27,457) | | |

New in FY2025

| Tennessee | | | | | | 25 | | | | | | 2,303 | | | | | | 454,341 | | | | | | 77,128 | | | | | | (25,850) | | |

New in FY2025

| Colorado | | | | | | 23 | | | | | | 1,516 | | | | | | 441,756 | | | | | | 61,171 | | | | | | (32,851) | | |

New in FY2025

| Georgia | | | | | | 15 | | | | | | 1,386 | | | | | | 444,275 | | | | | | 58,944 | | | | | | (19,593) | | |

New in FY2025

| Kentucky | | | | | | 21 | | | | | | 2,014 | | | | | | 380,975 | | | | | | 68,314 | | | | | | (22,151) | | |

New in FY2025

| Other (35 states) | | | | | | 273 | | | | | | 16,269 | | | | | | 4,564,352 | | | | | | 604,135 | | | | | | (184,290) | | |

New in FY2025

| *Total outpatient medical* | | | | | | 486 | | | | | | 34,582 | | | | | | $ | 8,866,971 | | | | | $ | 1,273,505 | | | | | $ | (424,141) | |

New in FY2025

| California | | | | | | 112 | | | | | | 8,532 | | | | | | $ | 6,481,573 | | | | | $ | 596,098 | | | | | $ | (171,358) | |

New in FY2025

| Massachusetts | | | | | | 19 | | | | | | 2,613 | | | | | | 2,902,117 | | | | | | 255,071 | | | | | | (72,528) | | |

New in FY2025

| Other (1 state) | | | | | | 4 | | | | | | — | | | | | | 100 | | | | | | 8,851 | | | | | | (1,273) | | |

New in FY2025

| *Total lab* | | | | | | 135 | | | | | | 11,145 | | | | | | $ | 9,383,790 | | | | | $ | 860,020 | | | | | $ | (245,159) | |

New in FY2025

| *Senior housing:* | | | | | | | | | | | | *(Units)* | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| Florida | | | | | | 9 | | | | | | 4,780 | | | | | | $ | 1,477,423 | | | | | $ | 388,390 | | | | | $ | (290,469) | |

New in FY2025

| Other (5 states) | | | | | | 6 | | | | | | 2,287 | | | | | | 674,697 | | | | | | 215,599 | | | | | | (157,385) | | |

New in FY2025

| *Total senior housing* | | | | | | 15 | | | | | | 7,067 | | | | | | $ | 2,152,120 | | | | | $ | 603,989 | | | | | $ | (447,854) | |

New in FY2025

| *Other non-reportable:* | | | | | | | | | | | | *(Sq. Ft.)* | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| Other (3 states) | | | | | | 3 | | | | | | 1,025 | | | | | | $ | 208,657 | | | | | $ | 23,218 | | | | | $ | (11,945) | |

New in FY2025

| *Total other non-reportable segments* | | | | | | 3 | | | | | | 1,025 | | | | | | $ | 208,657 | | | | | $ | 23,218 | | | | | $ | (11,945) | |

New in FY2025

| Total properties | | | | | | 639 | | | | | | | | | | | | $ | 20,611,538 | | | | | $ | 2,760,732 | | | | | $ | (1,129,099) | |

New in FY2025

| *Senior housing:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| *Other non-reportable:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| Average occupancy percentage(1) | | | 81 | | % | | | | 85 | | % | | | | 81 | | % | | | | | | | | | | | | |

New in FY2025

| Average annual rent per square foot(2) | | | $ | 34 | | | | | $ | 31 | | | | | $ | 38 | | | | | | | | | | | | | |

New in FY2025

| Average occupied square feet | | | 667 | | | | | | 664 | | | | | | 565 | | | | | | | | | | | | | | |

New in FY2025

| Square feet | | | | | | 31,619 | | | | | | 3,531 | | | | | | 3,017 | | | | | | 3,956 | | | | | | 3,104 | | | | | | 2,966 | | | | | | 2,952 | | | | | | 2,805 | | | | | | 1,545 | | | | | | 1,530 | | | | | | 1,745 | | | | | | 4,468 | | |

New in FY2025

| Base rent(2) | | | | | | $ | 845,505 | | | | | $ | 104,318 | | | | | $ | 86,880 | | | | | $ | 99,113 | | | | | $ | 91,240 | | | | | $ | 83,284 | | | | | $ | 75,200 | | | | | $ | 68,311 | | | | | $ | 45,331 | | | | | $ | 40,124 | | | | | $ | 34,624 | | | | | $ | 117,080 | |

New in FY2025

| Square feet | | | | | | 9,289 | | | | | | 552 | | | | | | 764 | | | | | | 578 | | | | | | 835 | | | | | | 1,195 | | | | | | 1,228 | | | | | | 817 | | | | | | 539 | | | | | | 984 | | | | | | 688 | | | | | | 1,109 | | |

New in FY2025

| Base rent(2) | | | | | | $ | 605,552 | | | | | $ | 36,221 | | | | | $ | 48,486 | | | | | $ | 32,982 | | | | | $ | 53,749 | | | | | $ | 85,643 | | | | | $ | 82,416 | | | | | $ | 58,776 | | | | | $ | 42,304 | | | | | $ | 72,830 | | | | | $ | 39,209 | | | | | $ | 52,936 | |

New in FY2025

| *Other non-reportable:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| Square feet | | | | | | 763 | | | | | | 164 | | | | | | 57 | | | | | | 47 | | | | | | 91 | | | | | | 106 | | | | | | 4 | | | | | | 85 | | | | | | — | | | | | | 66 | | | | | | 11 | | | | | | 132 | | |

New in FY2025

| Base rent(2) | | | | | | $ | 24,375 | | | | | $ | 7,076 | | | | | $ | 2,190 | | | | | $ | 1,205 | | | | | $ | 2,669 | | | | | $ | 3,371 | | | | | $ | 95 | | | | | $ | 3,652 | | | | | $ | — | | | | | $ | 1,617 | | | | | $ | 271 | | | | | $ | 2,229 | |

New in FY2025

| % of segment base rent | | | | | | 100 | | | | | | 29 | | | | | | 9 | | | | | | 5 | | | | | | 11 | | | | | | 14 | | | | | | — | | | | | | 15 | | | | | | — | | | | | | 7 | | | | | | 1 | | | | | | 9 | | |

New in FY2025

| Base rent(2) | | | | | | $ | 1,475,432 | | | | | $ | 147,615 | | | | | $ | 137,556 | | | | | $ | 133,300 | | | | | $ | 147,658 | | | | | $ | 172,298 | | | | | $ | 157,711 | | | | | $ | 130,739 | | | | | $ | 87,635 | | | | | $ | 114,571 | | | | | $ | 74,104 | | | | | $ | 172,245 | |

Dropped from FY2024

| Texas | | | | | | 103 | | | | | | 9,333 | | | | | | $ | 2,103,743 | | | | | $ | 295,840 | | | | | $ | (99,990) | |

Dropped from FY2024

| Florida | | | | | | 39 | | | | | | 2,206 | | | | | | 584,475 | | | | | | 72,769 | | | | | | (25,323) | | |

Dropped from FY2024

| Pennsylvania | | | | | | 15 | | | | | | 1,613 | | | | | | 456,194 | | | | | | 42,747 | | | | | | (17,205) | | |

Dropped from FY2024

| Tennessee | | | | | | 25 | | | | | | 2,348 | | | | | | 441,428 | | | | | | 71,504 | | | | | | (23,695) | | |

Dropped from FY2024

| Colorado | | | | | | 23 | | | | | | 1,443 | | | | | | 425,430 | | | | | | 54,562 | | | | | | (32,255) | | |

Dropped from FY2024

| Georgia | | | | | | 14 | | | | | | 1,418 | | | | | | 398,723 | | | | | | 43,848 | | | | | | (14,281) | | |

Dropped from FY2024

| Other (36 States) | | | | | | 288 | | | | | | 17,682 | | | | | | 4,646,540 | | | | | | 624,474 | | | | | | (193,244) | | |

Dropped from FY2024

| *Total outpatient medical* | | | | | | 507 | | | | | | 36,043 | | | | | | $ | 9,056,533 | | | | | $ | 1,205,744 | | | | | $ | (405,993) | |

Dropped from FY2024

| California | | | | | | 106 | | | | | | 7,862 | | | | | | $ | 5,919,953 | | | | | $ | 632,860 | | | | | $ | (162,212) | |

Dropped from FY2024

| Massachusetts | | | | | | 19 | | | | | | 2,613 | | | | | | 2,838,593 | | | | | | 241,376 | | | | | | (73,290) | | |

Dropped from FY2024

| Other (1 State) | | | | | | 4 | | | | | | 240 | | | | | | 54,239 | | | | | | 7,216 | | | | | | (4,118) | | |

Dropped from FY2024

| *Total lab* | | | | | | 129 | | | | | | 10,715 | | | | | | $ | 8,812,785 | | | | | $ | 881,452 | | | | | $ | (239,620) | |

Dropped from FY2024

| *CCRC:* | | | | | | | | | | | | *(Units)* | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2024

| Florida | | | | | | 9 | | | | | | 4,774 | | | | | | $ | 1,395,819 | | | | | $ | 367,604 | | | | | $ | (282,500) | |

Dropped from FY2024

| Other (5 States) | | | | | | 6 | | | | | | 2,286 | | | | | | 649,297 | | | | | | 200,871 | | | | | | (146,748) | | |

Dropped from FY2024

| *Total CCRC* | | | | | | 15 | | | | | | 7,060 | | | | | | $ | 2,045,116 | | | | | $ | 568,475 | | | | | $ | (429,248) | |

Dropped from FY2024

| Total properties | | | | | | 651 | | | | | | | | | | | | $ | 19,914,434 | | | | | $ | 2,655,671 | | | | | $ | (1,074,861) | |

Dropped from FY2024

| *CCRC:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2024

Average annual rent excludes termination fees and non-cash revenue adjustments (i.e., the impact of deferred community fee income).

Dropped from FY2024

| Square feet | | | | | | 33,278 | | | | | | 3,788 | | | | | | 4,090 | | | | | | 3,066 | | | | | | 3,930 | | | | | | 3,177 | | | | | | 2,237 | | | | | | 2,590 | | | | | | 2,710 | | | | | | 1,668 | | | | | | 1,494 | | | | | | 4,528 | | |

Dropped from FY2024

| Base rent(2) | | | | | | $ | 873,741 | | | | | $ | 104,756 | | | | | $ | 116,522 | | | | | $ | 85,332 | | | | | $ | 96,518 | | | | | $ | 92,462 | | | | | $ | 60,431 | | | | | $ | 65,266 | | | | | $ | 63,952 | | | | | $ | 47,918 | | | | | $ | 38,004 | | | | | $ | 102,580 | |

Dropped from FY2024

| Square feet | | | | | | 9,167 | | | | | | 675 | | | | | | 401 | | | | | | 1,030 | | | | | | 694 | | | | | | 844 | | | | | | 1,143 | | | | | | 1,050 | | | | | | 969 | | | | | | 594 | | | | | | 693 | | | | | | 1,074 | | |

Dropped from FY2024

| Base rent(2) | | | | | | $ | 572,298 | | | | | $ | 35,987 | | | | | $ | 28,059 | | | | | $ | 55,900 | | | | | $ | 37,850 | | | | | $ | 53,436 | | | | | $ | 79,287 | | | | | $ | 70,497 | | | | | $ | 63,067 | | | | | $ | 47,263 | | | | | $ | 52,233 | | | | | $ | 48,719 | |

Dropped from FY2024

| Base rent(2) | | | | | | $ | 1,446,039 | | | | | $ | 140,743 | | | | | $ | 144,581 | | | | | $ | 141,232 | | | | | $ | 134,368 | | | | | $ | 145,898 | | | | | $ | 139,718 | | | | | $ | 135,763 | | | | | $ | 127,019 | | | | | $ | 95,181 | | | | | $ | 90,237 | | | | | $ | 151,299 | |

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

16 rewritten, 10 added, 17 removed, 20 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

| | | | [removed: 2024] [added: 2021] | | | | | | [added: 2022 | | | | | |] 2023 | | | | | | [removed: 2022] [added: 2024] | | | [added: | | | 2025 | | |]

Rewritten

| Ordinary dividends(1) | | | $ | [removed: 0.720440] [added: 0.848632] | | | | | $ | [removed: 0.909692] [added: 0.720440] | | | | | $ | [removed: 0.872948] [added: 0.909692] | |

Rewritten

| Capital gains(2)(3) | | | [removed: 0.295060] [added: 0.051744] | | | | | | [removed: 0.116992] [added: 0.295060] | | | | | | [removed: 0.183208] [added: 0.116992] | | |

Rewritten

| Nondividend distributions | | | [removed: 0.184500] [added: 0.319654] | | | | | | [removed: 0.173316] [added: 0.184500] | | | | | | [removed: 0.143844] [added: 0.173316] | | |

Rewritten

| | | | $ | [removed: 1.200000] [added: 1.220030] | | | | | $ | 1.200000 | | | | | $ | 1.200000 | |

Rewritten

[removed: (1)For] [added: For] the year ended December 31, 2024, all $0.720440 of ordinary dividends qualified as business income for purposes of Code Section 199A.

Rewritten

[removed: For] [added: (1)For] the year ended December 31, [removed: 2022, all $0.872948] [added: 2025, the amount includes $0.782764] of ordinary dividends qualified as business income for purposes of Code Section [removed: 199A.][added: 199A and $0.065868 of qualified dividend income for purposes of Code Section 1(h)(11).]

Rewritten

(2)For the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022,] [added: 2023,] the amount includes [added: $0.047796,] $0.215960, [removed: $0.036256,] and [removed: $0.017760,] [added: $0.036256,] respectively, of unrecaptured Code Section 1250 gain.

Rewritten

Code Section 1061 is generally applicable to direct and indirect holders of “applicable partnership interests.” For [added: each of] the years ended December 31, [added: 2025,] 2024 and 2023, the “One Year Amounts” and “Three Year Amounts” are each zero, since all capital gains relate to Code Section 1231 gains.

Rewritten

(3)For [added: each of] the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022, 100%, 100%, and 10.3292%, respectively,] [added: 2023, 100%] of the capital gain distributions represent gains from dispositions of U.S. real property interests pursuant to Code Section 897 for foreign shareholders.

Rewritten

[removed: (1)On] [added: On] July 24, 2024, our Board of Directors approved the 2024 Share Repurchase Program under which we may acquire shares of our common stock in the open market or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act), up to an aggregate purchase price of $500 million.

Rewritten

[removed: Therefore, at] [added: At] December 31, [removed: 2024, $500] [added: 2025, $406] million of [removed: the Company’s] [added: our] common stock remained available for repurchase under the 2024 Share Repurchase Program.

Rewritten

The graph and table below compare the cumulative total return of Healthpeak, the S&P 500 Index, and the Equity REIT Index of Nareit, from January 1, [removed: 2020] [added: 2021] to December 31, [removed: 2024.][added: 2025.]

Rewritten

Total cumulative return is based on a $100 investment in Healthpeak common stock and in each of the indices at the close of trading on December 31, [removed: 2019] [added: 2020] and assumes quarterly reinvestment of dividends before consideration of income taxes.

Rewritten

(JANUARY 1, [removed: 2020] [added: 2021] = $100)

Rewritten

[removed: ![5047](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/peak-20241231_g1.jpg)][added: ![5236](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/peak-20251231_g1.jpg)]

New in FY2025

As of January 28, 2026, we had 6,166 stockholders of record.

New in FY2025

Commencing in April 2025, our Board of Directors transitioned to a practice of paying the quarterly common stock cash dividend on a monthly basis, which are declared quarterly.

New in FY2025

| | | | 2025 | | | | | | 2024 | | | | | | 2023 | | |

New in FY2025

On January 4, 2026, our Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of January, February, and March 2026, payable on January 30, 2026, February 27, 2026, and March 31, 2026, respectively, to stockholders of record as of the close of business on January 16, 2026, February 13, 2026, and March 17, 2026, respectively.

New in FY2025

During the three months ended December 31, 2025, there were no repurchases of common stock under the 2024 Share Repurchase Program.

New in FY2025

During the year ended December 31, 2025, we repurchased 5.09 million shares of our common stock at a weighted average price of $18.50 per share for a total of $94 million.

New in FY2025

JANUARY 1, 2021–DECEMBER 31, 2025

New in FY2025

| FTSE Nareit Equity REIT Index | | | $ | 141.30 | | | | | $ | 106.05 | | | | | $ | 118.09 | | | | | $ | 123.90 | | | | | $ | 126.72 | |

New in FY2025

| S&P 500 | | | 128.68 | | | | | | 105.36 | | | | | | 133.03 | | | | | | 166.28 | | | | | | 195.98 | | |

New in FY2025

| Healthpeak Properties, Inc. | | | 123.75 | | | | | | 89.71 | | | | | | 74.99 | | | | | | 81.63 | | | | | | 69.25 | | |

Dropped from FY2024

As of January 29, 2025, we had 6,645 stockholders of record, and there were 447,008 beneficial holders of our common stock.

Dropped from FY2024

For the year ended December 31, 2022, the “One Year Amounts” and “Three Year Amounts” are each 89.6708% of the total capital gain distributions and the remaining capital gain distributions are attributable to Code Section 1231 gains, which are not subject to Code Section 1061.

Dropped from FY2024

On February 3, 2025, our Board of Directors declared a quarterly common stock cash dividend of $0.305 per share, reflecting an increase from $0.30 to $0.305 per share.

Dropped from FY2024

The common stock cash dividend will be paid on February 26, 2025 to stockholders of record as of the close of business on February 14, 2025.

Dropped from FY2024

The following table sets forth information with respect to purchases of our common stock made by or on our behalf during the three months ended December 31, 2024.

Dropped from FY2024

| Period Covered | | | | | | Total Number of Shares Purchased | | | | | | Average Price Paid per Share | | | | | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | | | | | | Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs(1) | | |

Dropped from FY2024

| October 1-31, 2024 | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 500,000,000 | |

Dropped from FY2024

| November 1-30, 2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | 500,000,000 | | |

Dropped from FY2024

| December 1-31, 2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | 500,000,000 | | |

Dropped from FY2024

| | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 500,000,000 | |

Dropped from FY2024

_______________________________________

Dropped from FY2024

As of December 31, 2024, no shares have been repurchased under the 2024 Share Repurchase Program.

Dropped from FY2024

JANUARY 1, 2020–DECEMBER 31, 2024

Dropped from FY2024

| | | | 2020 | | | | | | 2021 | | | | | | 2022 | | | | | | 2023 | | | | | | 2024 | | |

Dropped from FY2024

| FTSE Nareit Equity REIT Index | | | $ | 94.88 | | | | | $ | 134.06 | | | | | $ | 100.62 | | | | | $ | 112.04 | | | | | $ | 117.56 | |

Dropped from FY2024

| S&P 500 | | | 118.39 | | | | | | 152.34 | | | | | | 124.73 | | | | | | 157.48 | | | | | | 196.85 | | |

Dropped from FY2024

| Healthpeak Properties, Inc. | | | 92.33 | | | | | | 114.25 | | | | | | 82.83 | | | | | | 69.24 | | | | | | 75.37 | | |

Item 8. Financial Statements and Supplementary Data

1,037 rewritten, 645 added, 690 removed, 979 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | | | [removed: [68](#id87c1e19981e404fb2b458e86ff35366_106)] [added: [73](#i9f4d17dc3a4a44b6ac4ecd42a230a144_106)] | | |

Rewritten

| [Consolidated Balance [removed: Sheets—](#id87c1e19981e404fb2b458e86ff35366_109)December] [added: Sheets—](#i9f4d17dc3a4a44b6ac4ecd42a230a144_109)December] 31, [added: 2025 [and](#i9f4d17dc3a4a44b6ac4ecd42a230a144_109)] 2024 [removed: [and](#id87c1e19981e404fb2b458e86ff35366_109) 2023] | | | [removed: [70](#id87c1e19981e404fb2b458e86ff35366_109)] [added: [75](#i9f4d17dc3a4a44b6ac4ecd42a230a144_109)] | | |

Rewritten

| [Consolidated Statements of Operations—for the years [removed: ended](#id87c1e19981e404fb2b458e86ff35366_112)] [added: ended](#i9f4d17dc3a4a44b6ac4ecd42a230a144_112)] December 31, [removed: 2024[,](#id87c1e19981e404fb2b458e86ff35366_112) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_112) 2022] [added: 2025[,](#i9f4d17dc3a4a44b6ac4ecd42a230a144_112) 2024[, and](#i9f4d17dc3a4a44b6ac4ecd42a230a144_112) 2023] | | | [removed: [71](#id87c1e19981e404fb2b458e86ff35366_112)] [added: [76](#i9f4d17dc3a4a44b6ac4ecd42a230a144_112)] | | |

Rewritten

| [Consolidated Statements of Comprehensive Income (Loss)—for the years [removed: ended](#id87c1e19981e404fb2b458e86ff35366_115)] [added: ended](#i9f4d17dc3a4a44b6ac4ecd42a230a144_115)] December 31, [removed: 2024[,](#id87c1e19981e404fb2b458e86ff35366_115) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_115) 2022] [added: 2025[,](#i9f4d17dc3a4a44b6ac4ecd42a230a144_115) 2024[, and](#i9f4d17dc3a4a44b6ac4ecd42a230a144_115) 2023] | | | [removed: [72](#id87c1e19981e404fb2b458e86ff35366_115)] [added: [77](#i9f4d17dc3a4a44b6ac4ecd42a230a144_115)] | | |

Rewritten

| [Consolidated Statements of Equity and Redeemable Noncontrolling Interests—for the years [removed: ended](#id87c1e19981e404fb2b458e86ff35366_118)] [added: ended](#i9f4d17dc3a4a44b6ac4ecd42a230a144_118)] December 31, [removed: 2024[,](#id87c1e19981e404fb2b458e86ff35366_118) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_118) 2022] [added: 2025[,](#i9f4d17dc3a4a44b6ac4ecd42a230a144_118) 2024[, and](#i9f4d17dc3a4a44b6ac4ecd42a230a144_118) 2023] | | | [removed: [73](#id87c1e19981e404fb2b458e86ff35366_118)] [added: [78](#i9f4d17dc3a4a44b6ac4ecd42a230a144_118)] | | |

Rewritten

| [Consolidated Statements of Cash Flows—for the years [removed: ended](#id87c1e19981e404fb2b458e86ff35366_121)] [added: ended](#i9f4d17dc3a4a44b6ac4ecd42a230a144_121)] December 31, [removed: 2024[,](#id87c1e19981e404fb2b458e86ff35366_121) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_121) 2022] [added: 2025[,](#i9f4d17dc3a4a44b6ac4ecd42a230a144_121) 2024[, and](#i9f4d17dc3a4a44b6ac4ecd42a230a144_121) 2023] | | | [removed: [75](#id87c1e19981e404fb2b458e86ff35366_121)] [added: [80](#i9f4d17dc3a4a44b6ac4ecd42a230a144_121)] | | |

Rewritten

| [Notes to the Consolidated Financial [removed: Statements](#id87c1e19981e404fb2b458e86ff35366_124)] [added: Statements](#i9f4d17dc3a4a44b6ac4ecd42a230a144_124)] | | | [removed: [76](#id87c1e19981e404fb2b458e86ff35366_124)] [added: [81](#i9f4d17dc3a4a44b6ac4ecd42a230a144_124)] | | |

Rewritten

[removed: To] [added: To] the stockholders and the Board of Directors of Healthpeak Properties, [removed: Inc.][added: Inc.]

Rewritten

We have audited the accompanying Consolidated Balance Sheets of Healthpeak Properties, Inc. and subsidiaries (the [removed: “Company”)] [added: "Company")] as of December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] the related Consolidated Statements of Operations, Comprehensive Income (Loss), Equity and Redeemable Noncontrolling Interests, and Cash Flows, for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] and the related Notes and the schedules listed in the Index at Item 15 (collectively referred to as the [removed: “financial statements”).][added: "financial statements").]

Rewritten

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] in conformity with accounting principles generally accepted in the United States of America.

Rewritten

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the [removed: Company’s] [added: Company's] internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in [removed: *Internal] [added: Internal] Control — Integrated Framework [removed: (2013)*] [added: (2013)] issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 4, 2025,] [added: 3, 2026] expressed an unqualified opinion on the [removed: Company’s] [added: Company's] internal control over financial reporting.

Rewritten

The [removed: Company’s evaluation of impairment of real estate involves an assessment of] [added: Company assesses] the carrying value of [added: its] real estate assets and related intangibles (“real estate assets”) when events or changes in circumstances indicate that the carrying value may not be recoverable.

Rewritten

Given the Company’s evaluation of [removed: impairment indicators, forecasted cash flows, and sales prices of a long-lived asset] [added: fair value relative to the impaired investments] requires management to make significant estimates and assumptions [removed: related to] [added: such as] market [removed: capitalization] [added: rents, expense] rates, [removed: market prices per unit, and/or] forecasted [removed: cash flows,] [added: occupancy, capitalization rates, and discount rates,] performing audit procedures required a high degree of auditor judgment and an increased extent of [removed: effort.][added: effort, including the need to involve our fair value specialists.]

Rewritten

- We tested the effectiveness of controls over impairment of real estate assets, including those over identifying impairment indicators, and the determination of [removed: forecasted] [added: estimated future] undiscounted cash [removed: flows and sales prices for real estate assets.][added: flows.]

Rewritten

- We performed an independent search for impairment indicators through the evaluation of several [removed: factors] [added: factors,] including an analysis of industry and market data and trends in financial performance.

Rewritten

[removed: |] /s/ [removed: DELOITTE] [added: Deloitte] & [removed: TOUCHE] [added: Touche] LLP [removed: | | | | | |]

Rewritten

[added: |] February [removed: 4,] [added: 3,] 2025 [added: | | | | | | $ | 348,194 | | | | | 3.40 | | % | | | | 2025 | | |]

Rewritten

| | | | [added: 2025 | | | | | |] 2024 | | | | | | 2023 | | |

Rewritten

| Buildings and improvements | | | $ | [removed: 16,115,283] [added: 16,593,535] | | | | | $ | [removed: 13,329,464] [added: 16,115,283] | |

Rewritten

| Development costs and construction in progress | | | [removed: 880,393] [added: 1,010,657] | | | | | | [removed: 643,217] [added: 880,393] | | |

Rewritten

| Land and improvements | | | [removed: 2,918,758] [added: 3,007,346] | | | | | | [removed: 2,647,633] [added: 2,918,758] | | |

Rewritten

| Accumulated depreciation [removed: and amortization] | | | [removed: (4,083,030)] [added: (4,512,443)] | | | | | | [removed: (3,591,951)] [added: (4,083,030)] | | |

Rewritten

| Net real estate | | | [removed: 15,831,404] [added: 16,099,095] | | | | | | [removed: 13,028,363] [added: 15,831,404] | | |

Rewritten

| Investments in [removed: and advances to] unconsolidated joint ventures | | | [removed: 936,814] [added: 802,601] | | | | | | [removed: 782,853] [added: 936,814] | | |

Rewritten

| Accounts receivable, net of allowance of [removed: $2,243] [added: $2,018] and [removed: $2,282] [added: $2,243] | | | [removed: 76,810] [added: 78,327] | | | | | | [removed: 55,820] [added: 76,810] | | |

Rewritten

| Cash and cash equivalents | | | 119,818 | | | | | | 117,635 | | | [added: | | | 72,032 | | |]

Rewritten

| Restricted cash | | | 64,487 | | | | | | 51,388 | | | [added: | | | 54,802 | | |]

Rewritten

| Intangible [removed: assets, net] [added: assets] | | | [removed: 817,254] [added: 654,516] | | | | | | [removed: 314,156] [added: 817,254] | | |

Rewritten

| Assets held for [removed: sale, net] [added: sale] | | | [removed: 7,840] [added: 80,621] | | | | | | [removed: 117,986] [added: 7,840] | | |

Rewritten

| Right-of-use [removed: asset, net] [added: asset] | | | [removed: 424,173] [added: 412,198] | | | | | | [removed: 240,155] [added: 424,173] | | |

Rewritten

| Total assets | | | $ | [removed: 19,938,255] [added: 20,336,018] | | | | | $ | [removed: 15,698,850] [added: 19,938,255] | |

Rewritten

| Bank line of credit and commercial paper | | | $ | [removed: 150,000] [added: 1,078,850] | | | | | $ | [removed: 720,000] [added: 150,000] | |

Rewritten

| Term loans | | | [removed: 1,646,043] [added: 1,647,113] | | | | | | [removed: 496,824] [added: 1,646,043] | | |

Rewritten

| Senior unsecured notes | | | [removed: 6,563,256] [added: 6,772,722] | | | | | | [removed: 5,403,378] [added: 6,563,256] | | |

Rewritten

| Mortgage debt | | | [removed: 356,750] [added: 349,209] | | | | | | [removed: 256,097] [added: 356,750] | | |

Rewritten

| Intangible [removed: liabilities, net] [added: liabilities] | | | [removed: 191,884] [added: 173,697] | | | | | | [removed: 127,380] [added: 191,884] | | |

Rewritten

| Liabilities related to assets held for [removed: sale, net] [added: sale] | | | [removed: —] [added: 11,900] | | | | | | [removed: 729] [added: —] | | |

Rewritten

| Lease liability | | | [removed: 307,220] [added: 296,260] | | | | | | [removed: 206,743] [added: 307,220] | | |

Rewritten

| Accounts payable, accrued liabilities, and other liabilities | | | [removed: 725,342] [added: 718,509] | | | | | | [removed: 657,196] [added: 725,342] | | |

Rewritten

| Deferred revenue | | | [removed: 940,136] [added: 985,307] | | | | | | [removed: 905,633] [added: 940,136] | | |

New in FY2025

Recoverability of real estate assets is measured by comparing the carrying amount of the real estate assets to the respective estimated future undiscounted cash flows.

New in FY2025

In performing this evaluation, the Company considers external market factors and makes assumptions regarding external market conditions, forecasted cash flows, and intent with respect to the holding or disposing of the asset.

New in FY2025

The estimated future undiscounted cash flows may be probability-weighted to reflect multiple possible cash-flow scenarios.

New in FY2025

The determination of forecasted cash flows involves significant assumptions including market capitalization rates, growth rates, lease revenue rates, expense rates, and probability weighting to different possible scenarios, if applicable.

New in FY2025

During the year ended December 31, 2025, the Company did not recognize any impairment charges on its consolidated real estate assets.

New in FY2025

We identified the impairment of real estate assets as a critical audit matter because of the significant estimates and assumptions management makes to evaluate the recoverability of real estate assets.

New in FY2025

This required a high degree of auditor judgment and an increased extent of effort, when performing audit procedures to evaluate the reasonableness of management’s estimated future undiscounted cash flows, including significant assumptions relating to the intended hold period, market capitalization rates, growth rates, lease revenue rates, and probability weighting of different possible scenarios, if applicable.

New in FY2025

- We evaluated management’s determination of estimated future undiscounted cash flows used in evaluating recoverability by (1) evaluating the source information used by management, (2) testing the mathematical accuracy of the estimated future undiscounted cash flow models, and (3) evaluating management’s significant assumptions, such as the intended hold period, market capitalization rates, growth rates, lease revenue rates, and probability weighting of different possible scenarios, if applicable.

New in FY2025

Impairments – Investments in Unconsolidated Joint Ventures – Refer to Notes 2 and 9 to the financial statements

New in FY2025

The Company reviews its equity method investments for indicators of impairment.

New in FY2025

The Company’s fair values of its equity method investments are determined based on discounted cash flow models, which requires management to make significant estimates and assumptions related to market rents, expense rates, forecasted occupancy, capitalization rates, discount rates, expected capital expenditures, comparable sales data, among other things.

New in FY2025

The Company concluded that the decline in fair value of certain equity method investments was other-than-temporary and recorded impairment charges of $178 million for the year ended December 31, 2025, which is included in “Equity income (loss) from unconsolidated joint ventures” within the Consolidated Statements of Operation.

New in FY2025

Our audit procedures related to the impairment of investment in unconsolidated joint ventures included the following, among others:

New in FY2025

- We tested the effectiveness of controls over management’s evaluation of impairment of its investments in unconsolidated joint ventures and measurement of that impairment based on discounted cash flows.

New in FY2025

- With the assistance of our fair value specialists, we evaluated the discounted cash flows analyses, including estimates of market rents, expense rates, forecasted occupancy, capitalization rates, and discount rates by (1) evaluating the valuation methodology, (2) evaluating the source information and assumptions used by management, and (3) testing the mathematical accuracy of the discounted cash flows analysis.

New in FY2025

February 3, 2026

New in FY2025

| Loans receivable, net of reserves of $11,345 and $10,499 | | | 606,020 | | | | | | 655,917 | | |

New in FY2025

| Cash and cash equivalents | | | 467,457 | | | | | | 119,818 | | |

New in FY2025

| Deferred tax assets | | | 111,248 | | | | | | 115,258 | | |

New in FY2025

| Goodwill | | | 68,529 | | | | | | 68,529 | | |

New in FY2025

| Other assets | | | 885,161 | | | | | | 819,951 | | |

New in FY2025

| Basic | | | $ | 0.10 | | | | | $ | 0.36 | | | | | $ | 0.56 | |

New in FY2025

| Diluted | | | $ | 0.10 | | | | | $ | 0.36 | | | | | $ | 0.56 | |

New in FY2025

| December 31, 2024 | | | 699,485 | | | | | | $ | 699,485 | | | | | $ | 12,847,252 | | | | | $ | (5,174,279) | | | | | $ | 28,818 | | | | | $ | 8,401,276 | | | | | $ | 653,738 | | | | | $ | 9,055,014 | | | | | $ | 2,610 | |

New in FY2025

| Net income (loss) | | | — | | | | | | — | | | | | | — | | | | | | 71,347 | | | | | | — | | | | | | 71,347 | | | | | | 29,986 | | | | | | 101,333 | | | | | | (306) | | |

New in FY2025

| Issuance of common stock, net | | | 596 | | | | | | 596 | | | | | | 1,443 | | | | | | — | | | | | | — | | | | | | 2,039 | | | | | | — | | | | | | 2,039 | | | | | | — | | |

New in FY2025

| Conversion of non-managing member units to common stock | | | 191 | | | | | | 191 | | | | | | 4,306 | | | | | | — | | | | | | — | | | | | | 4,497 | | | | | | (4,497) | | | | | | — | | | | | | — | | |

New in FY2025

| Repurchase of common stock | | | (5,235) | | | | | | (5,235) | | | | | | (91,910) | | | | | | — | | | | | | — | | | | | | (97,145) | | | | | | — | | | | | | (97,145) | | | | | | — | | |

New in FY2025

| Increase in noncontrolling interests from acquisitions | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 131,974 | | |

New in FY2025

| December 31, 2025 | | | 695,037 | | | | | | $ | 695,037 | | | | | $ | 12,767,914 | | | | | $ | (5,952,920) | | | | | $ | (9,937) | | | | | $ | 7,500,094 | | | | | $ | 642,776 | | | | | $ | 8,142,870 | | | | | $ | 159,581 | |

New in FY2025

| Amortization of above (below) market lease intangibles | | | (36,747) | | | | | | (30,755) | | | | | | (25,791) | | | | | |

New in FY2025

| Amortization of non-refundable entrance fees | | | (98,912) | | | | | | (88,995) | | | | | | (83,197) | | | | | |

New in FY2025

| Increase (decrease) in accounts payable, accrued liabilities, and other liabilities | | | (25,285) | | | | | | (28,640) | | | | | | (40,732) | | | | | |

New in FY2025

| Increase (decrease) in deferred revenue | | | 147,297 | | | | | | 114,275 | | | | | | 145,243 | | | | | |

New in FY2025

| Cash, cash equivalents, and restricted cash, end of year | | | $ | 537,702 | | | | | $ | 184,305 | | | | | $ | 169,023 | | | | |

New in FY2025

In December 2025, the Company confidentially submitted a draft registration statement on Form S-11 to the United States Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering (the “Offering” or “Janus Living Offering”) of shares of common stock of a newly formed company, Janus Living, Inc. (“Janus Living”), which will be dedicated to senior housing and which intends to elect and qualify to be taxed as a REIT.

New in FY2025

The Company will contribute its 34-community senior housing portfolio to Janus Living in exchange for a majority ownership interest in Janus Living.

New in FY2025

Immediately following the Janus Living Offering, the Company will serve as its external manager and intends to retain a substantial majority interest in Janus Living, with new public shareholders owning the remaining interest.

New in FY2025

These amounts are due from residents, third-party payors (including health insurers and government programs, such as Medicare and Medicaid), and others.

New in FY2025

Revenue is recognized as performance obligations are satisfied, and the resident receives and controls the good or service.

Dropped from FY2024

Auditing the Company’s process to evaluate real estate assets for impairment was complex due to the subjectivity in determining whether impairment indicators were present.

Dropped from FY2024

Additionally, for real estate assets where indicators of impairment were determined to be present, the determination of the future undiscounted cash flows involved significant judgment.

Dropped from FY2024

In particular, the undiscounted cash flows were forecasted based on significant assumptions such as lease-up periods, lease revenue rates, operating expenses, and revenue and expense growth rates, and included judgments around the intended hold period and terminal capitalization rates.

Dropped from FY2024

- For real estate assets where indicators of impairment were determined to be present, we subjected a sample of undiscounted cash flow models to testing by (1) evaluating the source information and assumptions used by management, (2) testing the mathematical accuracy of the undiscounted cash flow models, and (3) evaluating management’s intended hold period.

Dropped from FY2024

Business Combination – Physicians Realty Trust Merger Valuation — Refer to Notes 2 and 3 to the financial statements

Dropped from FY2024

The Company completed the acquisition of Physicians Realty Trust on March 1, 2024 for total consideration of $3.0 billion.

Dropped from FY2024

The Company accounted for this acquisition as a business combination.

Dropped from FY2024

Accordingly, the purchase price was allocated to the assets acquired, liabilities assumed, and noncontrolling interests based on their relative fair values, including approximately $3.7 billion of consolidated real estate, $891 million in related intangible assets, and $150 million in related intangible liabilities.

Dropped from FY2024

The fair value determination of the real estate assets acquired and liabilities assumed required management to make significant estimates related to assumptions such as market land values, discount rates, capitalization rates, costs to execute similar leases, and fair market lease rates.

Dropped from FY2024

Given the fair value determination of assets acquired and liabilities assumed requires management to make significant estimates and assumptions such as market land values, discount rates, capitalization rates, costs to execute similar leases, and fair market lease rates, performing audit procedures to evaluate the reasonableness of these assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.

Dropped from FY2024

Our audit procedures related to the fair value of real estate assets acquired and liabilities assumed included the following, among others:

Dropped from FY2024

- We tested the effectiveness of controls over the purchase price allocation, including management’s controls over the identification of real estate assets, and the valuation methodology for estimating the fair value of real estate assets acquired and liabilities assumed.

Dropped from FY2024

- With the assistance of our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) relevant market data, and (3) assumptions used in the valuation of land, buildings, and related intangible assets and liabilities, including testing the mathematical accuracy of the calculations, and comparing management’s assumptions to independently validated data sources used by market participants.

Dropped from FY2024

- We assessed the accuracy and completeness of the underlying data used in the valuation of land, buildings, and related intangible assets and liabilities including in-place lease agreements, square footage, and historical operating data.

Dropped from FY2024

| Loans receivable, net of reserves of $10,499 and $2,830 | | | 717,190 | | | | | | 218,450 | | |

Dropped from FY2024

| Other assets, net | | | 942,465 | | | | | | 772,044 | | |

Dropped from FY2024

| Revenues: | | | | | | | | | | | | | | | | | |

Dropped from FY2024

| Income from direct financing leases | | | — | | | | | | — | | | | | | 1,168 | | |

Dropped from FY2024

| Costs and expenses: | | | | | | | | | | | | | | | | | |

Dropped from FY2024

| Income (loss) from discontinued operations | | | — | | | | | | — | | | | | | 2,884 | | |

Dropped from FY2024

| Continuing operations | | | $ | 0.36 | | | | | $ | 0.56 | | | | | $ | 0.92 | |

Dropped from FY2024

| Discontinued operations | | | — | | | | | | — | | | | | | 0.00 | | |

Dropped from FY2024

| Continuing operations | | | $ | 0.36 | | | | | $ | 0.56 | | | | | $ | 0.92 | |

Dropped from FY2024

| Discontinued operations | | | — | | | | | | — | | | | | | 0.00 | | |

Dropped from FY2024

| December 31, 2021 | | | 539,097 | | | | | | $ | 539,097 | | | | | $ | 10,100,294 | | | | | $ | (4,120,774) | | | | | $ | (3,147) | | | | | $ | 6,515,470 | | | | | $ | 543,290 | | | | | $ | 7,058,760 | | | | | $ | 87,344 | |

Dropped from FY2024

| Net income (loss) | | | — | | | | | | — | | | | | | — | | | | | | 500,449 | | | | | | — | | | | | | 500,449 | | | | | | 15,876 | | | | | | 516,325 | | | | | | 99 | | |

Dropped from FY2024

| Issuance of common stock, net | | | 9,936 | | | | | | 9,936 | | | | | | 299,481 | | | | | | — | | | | | | — | | | | | | 309,417 | | | | | | — | | | | | | 309,417 | | | | | | — | | |

Dropped from FY2024

| Conversion of DownREIT units to common stock | | | 27 | | | | | | 27 | | | | | | 853 | | | | | | — | | | | | | — | | | | | | 880 | | | | | | (880) | | | | | | — | | | | | | — | | |

Dropped from FY2024

| Repurchase of common stock | | | (2,418) | | | | | | (2,418) | | | | | | (65,420) | | | | | | — | | | | | | — | | | | | | (67,838) | | | | | | — | | | | | | (67,838) | | | | | | — | | |

Dropped from FY2024

| December 31, 2023 | | | 547,156 | | | | | | $ | 547,156 | | | | | $ | 10,405,780 | | | | | $ | (4,621,861) | | | | | $ | 19,371 | | | | | $ | 6,350,446 | | | | | $ | 525,596 | | | | | $ | 6,876,042 | | | | | $ | 48,828 | |

Dropped from FY2024

| Amortization of non-refundable entrance fees and above (below) market lease intangibles | | | (119,750) | | | | | | (108,988) | | | | | | (102,747) | | | | | |

Dropped from FY2024

| Loss (gain) on sale of real estate under direct financing leases | | | — | | | | | | — | | | | | | (22,693) | | | | | |

Dropped from FY2024

| Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue | | | 85,635 | | | | | | 104,511 | | | | | | 136,293 | | | | | |

Dropped from FY2024

| Proceeds from the Callan Ridge JV transaction, net | | | 125,662 | | | | | | — | | | | | | — | | | | | |

Dropped from FY2024

For additional information on the UPREIT Reorganization, see the Company’s Current Report on Form 8-K12B filed with the U.S. Securities and Exchange Commission (“SEC”) on February 10, 2023.

Dropped from FY2024

Residency agreements for SHOP and CCRC facilities are generally for a term of 30 days to one year, with resident fees billed monthly, in advance.

Dropped from FY2024

Revenue for certain care related services is recognized as services are provided and is billed monthly in arrears.

Dropped from FY2024

*Income from Direct Financing Leases*

Dropped from FY2024

The Company utilizes the direct finance method of accounting to record direct financing lease (“DFL”) income.

Dropped from FY2024

For a lease accounted for as a DFL, the net investment in the DFL represents receivables for the sum of future minimum lease payments and the estimated residual value of the leased property, less the unamortized unearned income.

An excerpt. Shown here: 40 of 1,037 rewritten, 40 of 645 added and 40 of 690 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2025 filing and the FY2024 filing.

Item 9A. Controls and Procedures

10 rewritten, 4 added, 1 removed, 20 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, [removed: 2024.][added: 2025.]

Rewritten

Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, [removed: 2024.][added: 2025.]

Rewritten

Based on our evaluation under the framework in *Internal Control—Integrated Framework (2013)*, our management concluded that our internal control over financial reporting was effective as of December 31, [removed: 2024.][added: 2025.]

Rewritten

The effectiveness of our internal control over financial reporting as of December 31, [removed: 2024] [added: 2025] has been audited by Deloitte & Touche LLP, the independent registered public accounting firm that audited the financial statements included in this Annual Report on Form 10-K, as stated in their report, which is included herein.

Rewritten

[removed: *Changes in Internal Control Over Financial Reporting.* There were] [added: Except for those changes, there have been] no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, [removed: 2024] [added: 2025] that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Rewritten

[removed: To] [added: To] the stockholders and the Board of Directors of Healthpeak Properties, [removed: Inc.][added: Inc.]

Rewritten

We have audited the internal control over financial reporting of Healthpeak Properties, Inc. and subsidiaries (the “Company”) as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Rewritten

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

Rewritten

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, [removed: 2024,] [added: 2025,] of the Company and our report dated February [removed: 4, 2025,] [added: 3, 2026,] expressed an unqualified opinion on those financial statements.

Rewritten

[removed: |] /s/ [removed: DELOITTE] [added: Deloitte] & [removed: TOUCHE] [added: Touche] LLP [removed: | | | | | |]

New in FY2025

*Changes in Internal Control Over Financial Reporting.* During the quarter ended June 30, 2025, we completed the implementation of a new enterprise resource planning (“ERP”) system to replace our previous ERP system.

New in FY2025

The implementation resulted in considerable changes to our processes and control environment, including the implementation of new applications, interfaces, and reports.

New in FY2025

The new ERP was used during the second, third, and fourth quarters of 2025, and the new and modified processes and controls implemented were used to prepare our consolidated financial statements for the year ended December 31, 2025 included in this report.

New in FY2025

February 3, 2026

Dropped from FY2024

February 4, 2025

Item 9B. Other Information

1 rewritten, 0 added, 0 removed, 1 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

During the three months ended December 31, [removed: 2024,] [added: 2025,] none of our directors or Section 16 officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement.

Item 10. Directors, Executive Officers and Corporate Governance

1 rewritten, 0 added, 0 removed, 4 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

Except as provided below, the information required under Item 10 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2024] [added: 2025] in connection with our [removed: 2025] [added: 2026] Annual Meeting of Stockholders.

Item 11. Executive Compensation

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

The information required under Item 11 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2024] [added: 2025] in connection with our [removed: 2025] [added: 2026] Annual Meeting of Stockholders.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

The information required under Item 12 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2024] [added: 2025] in connection with our [removed: 2025] [added: 2026] Annual Meeting of Stockholders.

Item 13. Certain Relationships and Related Transactions, and Director Independence

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

The information required under Item 13 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2024] [added: 2025] in connection with our [removed: 2025] [added: 2026] Annual Meeting of Stockholders.

Item 14. Principal Accountant Fees and Services

1 rewritten, 0 added, 0 removed, 1 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

The information required under Item 14 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2024] [added: 2025] in connection with our [removed: 2025] [added: 2026] Annual Meeting of Stockholders.

Item 15. Exhibits and Financial Statement Schedules

35 rewritten, 8 added, 6 removed, 80 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

Consolidated Balance Sheets - December 31, [removed: 2024] [added: 2025] and [removed: 2023][added: 2024]

Rewritten

Consolidated Statements of Operations - for the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022][added: 2023]

Rewritten

Consolidated Statements of Comprehensive Income (Loss) - for the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022][added: 2023]

Rewritten

Consolidated Statements of Equity and Redeemable Noncontrolling Interests - for the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022][added: 2023]

Rewritten

Consolidated Statements of Cash Flows - for the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022][added: 2023]

Rewritten

| 3.3 | | | | | | [Articles of Amendment of Healthpeak [removed: Propert](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-1.htm)[i](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-1.htm)[es,] [added: Properties,] Inc., effective February 29, 2024.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-1.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |

Rewritten

| 4.1.3 | | | | | | [removed: [T](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm)[hird] [added: [Third] Supplemental Indenture, dated as of March 1, 2024, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., [removed: as](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm) [guarantor](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm)[,] [added: as guarantor,] DOC DR Holdco, LLC, as guarantor, DOR DR, LLC, as guarantor, and the Bank of New York Mellon Trust [removed: Company](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm)[,] [added: Company,] N.A., as trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |

Rewritten

| 4.2 | | | | | | [Amended and Restated Indenture, dated as of February 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (amending and restating the Indenture, dated [removed: November 21,] [added: November](https://www.sec.gov/Archives/edgar/data/765880/000110465923018717/tm235984d25_ex4-6.htm) [19](https://www.sec.gov/Archives/edgar/data/765880/000110465923018717/tm235984d25_ex4-6.htm)[,] 2012, between Healthpeak and the trustee).](https://www.sec.gov/Archives/edgar/data/765880/000110465923018717/tm235984d25_ex4-6.htm) | | | | | | Registration Statement on Form S-3ASR (Registration No. 333‑269718) | | | | | | February 13, 2023 | | |

Rewritten

| [removed: 4.4] [added: 4.5] | | | | | | [Form of 6.750% Senior Notes due 2041.](https://www.sec.gov/Archives/edgar/data/765880/000110465911002678/a11-3301_5ex4d5.htm) | | | | | | Current Report on Form 8-K | | | | | | January 24, 2011 | | |

Rewritten

| [removed: 4.5] [added: 4.12] | | | | | | [Form of [removed: 3.400%] [added: 5.250%] Senior Notes due [removed: 2025.](https://www.sec.gov/Archives/edgar/data/765880/000110465915003694/a15-2154_5ex4d1.htm)] [added: 2032.](https://www.sec.gov/Archives/edgar/data/765880/000110465923004247/tm233500d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | January [removed: 21, 2015] [added: 17, 2023] | | |

Rewritten

| 4.6 | | | | | | [Form of [removed: 4.000%] [added: 3.250%] Senior Notes due [removed: 2025.](https://www.sec.gov/Archives/edgar/data/765880/000110465915039674/a15-9767_5ex4d1.htm)] [added: 2026.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] | | | | | | Current Report on Form 8-K | | | | | | [removed: May 20, 2015] [added: July 5, 2019] | | |

Rewritten

| 4.7 | | | | | | [Form of [removed: 3.250%] [added: 3.500%] Senior Notes due [removed: 2026.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] [added: 2029.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] | | | | | | Current Report on Form 8-K | | | | | | July 5, 2019 | | |

Rewritten

| 4.8 | | | | | | [Form of [removed: 3.500%] [added: 3.000%] Senior Notes due [removed: 2029.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] [added: 2030.](https://www.sec.gov/Archives/edgar/data/765880/000110465919066251/tm1923469d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: July 5,] [added: November 21,] 2019 | | |

Rewritten

| 4.9 | | | | | | [Form of [removed: 3.000%] [added: 2.875%] Senior Notes due [removed: 2030.](https://www.sec.gov/Archives/edgar/data/765880/000110465919066251/tm1923469d1_ex4-1.htm)] [added: 2031.](https://www.sec.gov/Archives/edgar/data/765880/000110465920076057/tm2023139d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: November 21, 2019] [added: June 23, 2020] | | |

Rewritten

| 4.10 | | | | | | [Form of [removed: 2.875%] [added: 1.350%] Senior Notes due [removed: 2031.](https://www.sec.gov/Archives/edgar/data/765880/000110465920076057/tm2023139d1_ex4-1.htm)] [added: 2027.](https://www.sec.gov/Archives/edgar/data/765880/000110465921091175/tm2120897d4_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: June 23, 2020] [added: July 12, 2021] | | |

Rewritten

| 4.11 | | | | | | [Form of [removed: 1.350%] [added: 2.125%] Senior Notes due [removed: 2027.](https://www.sec.gov/Archives/edgar/data/765880/000110465921091175/tm2120897d4_ex4-1.htm)] [added: 2028.](https://www.sec.gov/Archives/edgar/data/765880/000110465921143581/tm2132635d5_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: July 12,] [added: November 24,] 2021 | | |

Rewritten

| [removed: 4.12] [added: 4.15] | | | | | | [removed: [Form] [added: [F](https://www.sec.gov/Archives/edgar/data/765880/000110465925078628/tm2522422d7_ex4-1.htm)[orm] of [removed: 2.125%] [added: 4.75%] Senior Notes due [removed: 2028.](https://www.sec.gov/Archives/edgar/data/765880/000110465921143581/tm2132635d5_ex4-1.htm)] [added: 2033.](https://www.sec.gov/Archives/edgar/data/765880/000110465925078628/tm2522422d7_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: November 24, 2021] [added: August 14, 2025] | | |

Rewritten

| 4.13 | | | | | | [Form of 5.250% Senior Notes due [removed: 2032.](https://www.sec.gov/Archives/edgar/data/765880/000110465923004247/tm233500d1_ex4-1.htm)] [added: 2032, including the form of Notation of Guarantee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-2.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: January 17,] [added: May 10,] 2023 | | |

Rewritten

| 4.14 | | | | | | [Form of [removed: 5.250%] [added: 5.375%] Senior Notes due [removed: 2032, including the form of Notation of Guarantee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-2.htm)] [added: 2035](https://www.sec.gov/Archives/edgar/data/765880/000110465925014042/tm255424d9_ex4-2.htm)[.](https://www.sec.gov/Archives/edgar/data/765880/000110465925014042/tm255424d9_ex4-2.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: May 10, 2023] [added: February 14, 2025] | | |

Rewritten

| [removed: 4.15†] [added: 4.16†] | | | | | | [Description of Healthpeak Capital [removed: Stock.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex41512312024.htm)] [added: Stock.](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex41612312025.htm)] | | | | | | | | | | | | | | |

Rewritten

| 10.6 | | | | | | [removed: [A](https://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm)[t-the-Market] [added: [At-the-Market] Equity Offering Sales Agreement, dated February 17, 2023, among Healthpeak Properties, Inc., Healthpeak OP, LLC, and the sales agents, forward sellers and forward purchasers referred to therein.](https://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm) | | | | | | Current Report on Form 8-K | | | | | | February 17, 2023 | | |

Rewritten

| 10.6.2 | | | | | | [Amendment No. 2 to At-the-Market Equity Offering Sales Agreement, dated May 3, 2024, among Healthpeak Properties, Inc., Healthpeak OP, LLC, the Sales Agents, the Forward Sellers and the Forward [removed: Purchasers](https://www.sec.gov/Archives/edgar/data/765880/000162828024033154/ex10106302024.htm)[.](https://www.sec.gov/Archives/edgar/data/765880/000162828024033154/ex10106302024.htm)] [added: Purchasers.](https://www.sec.gov/Archives/edgar/data/765880/000162828024033154/ex10106302024.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | July 26, 2024 | | |

Rewritten

| 10.11.2* | | | | | | [Form of 2014 Performance Incentive Plan NEO Retentive LTIP [removed: RSU] [added: Unit] Agreement (adopted [removed: 2018).](https://www.sec.gov/Archives/edgar/data/765880/000155837015000716/hcp-20150331ex108280e48.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10703312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: May 3, 2018] [added: April 28, 2023] | | |

Rewritten

| 10.11.3* | | | | | | [Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based [removed: Restricted Stock] [added: LTIP] Unit Agreement (adopted [removed: 2022).](https://www.sec.gov/Archives/edgar/data/765880/000162828022012290/ex10103312022.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10803312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: May 4, 2022] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11.4*] [added: 10.12.7*] | | | | | | [Form of [removed: 2014] [added: 2023] Performance Incentive Plan [removed: NEO Retentive LTIP] [added: Non-NEO OP] Unit [added: Award] Agreement (adopted [removed: 2023).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10703312023.htm)] [added: 2025, for converted awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex1012712312024.htm)] | | | | | | [removed: Quarterly] [added: Annual] Report on Form [removed: 10-Q] [added: 10-K] | | | | | | [removed: April 28, 2023] [added: February 4, 2025] | | |

Rewritten

| [removed: 10.14] [added: 10.15] | | | | | | [Amended and Restated Dividend Reinvestment and Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/765880/000089843000003380/0000898430-00-003380-0004.txt) | | | | | | Registration Statement on Form S‑3 (Registration No. 333‑49746) | | | | | | November 13, 2000 | | |

Rewritten

| [removed: 10.15] [added: 10.16*] | | | | | | [Offer Letter, dated February 29, 2024, from Healthpeak Properties, LLC to John T. Thomas.](https://www.sec.gov/Archives/edgar/data/765880/000162828024018706/ex10803312024.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 26, 2024 | | |

Rewritten

| [removed: 19.1†] [added: 19.1] | | | | | | [Insider Trading Policy.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex19112312024.htm) | | | | | | [added: Annual Report on Form 10-K] | | | | | | [added: February 4, 2025] | | |

Rewritten

| 21.1† | | | | | | [Subsidiaries of the [removed: Company.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex21112312024.htm)] [added: Company.](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex21112312025.htm)] | | | | | | | | | | | | | | |

Rewritten

| [removed: 22.1†] [added: 22.1] | | | | | | [List of Issuers of Guaranteed [removed: Securities.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex22112312024.htm)] [added: Securities.](https://www.sec.gov/Archives/edgar/data/765880/000162828025046273/ex22109302025.htm)] | | | | | | [added: Quarterly Report on Form 10-Q] | | | | | | [added: October 24, 2025] | | |

Rewritten

| 23.1† | | | | | | [Consent of Independent Registered Public Accounting Firm—Deloitte & Touche [removed: LLP.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex23112312024.htm)] [added: LLP.](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex23112312025.htm)] | | | | | | | | | | | | | | |

Rewritten

| 31.1† | | | | | | [Certification by Scott M. Brinker, Healthpeak’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule [removed: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex31112312024.htm)] [added: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex31112312025.htm)] | | | | | | | | | | | | | | |

Rewritten

| 31.2† | | | | | | [Certification [removed: by Peter A. Scott,] [added: by](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex31212312025.htm) [Kelv](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex31212312025.htm)[in](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex31212312025.htm) [O. Moses](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex31212312025.htm)[,] Healthpeak’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule [removed: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex31212312024.htm)] [added: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex31212312025.htm)] | | | | | | | | | | | | | | |

Rewritten

| 32.1†† | | | | | | [Certification by Scott M. Brinker, Healthpeak’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a‑14(b) and 18 U.S.C. Section [removed: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex32112312024.htm).] [added: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex32112312025.htm).] | | | | | | | | | | | | | | |

Rewritten

| 32.2†† | | | | | | [Certification [removed: by Peter A. Scott,] [added: by](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex32212312025.htm) [Kelvin O. Moses](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex32212312025.htm)[,] Healthpeak’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a‑14(b) and 18 U.S.C. Section [removed: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex32212312024.htm).] [added: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828026005044/ex32212312025.htm).] | | | | | | | | | | | | | | |

New in FY2025

| 4.4 | | | | | | [Base Indenture, dated February 14, 2025, by and among Healthpeak OP, LLC, the Guarantors, and U.S. Bank Trust Company, National Association, as trustee](https://www.sec.gov/Archives/edgar/data/765880/000110465925014042/tm255424d9_ex4-1.htm)[.](https://www.sec.gov/Archives/edgar/data/765880/000110465925014042/tm255424d9_ex4-1.htm) | | | | | | Current Report on Form 8-K | | | | | | February 14, 2025 | | |

New in FY2025

| 4.4.1 | | | | | | [First Supplemental Indenture, dated February 14, 2025, by and among Healthpeak OP, LLC, the Guarantors, and U.S. Bank Trust Company, National Association, as trustee](https://www.sec.gov/Archives/edgar/data/765880/000110465925014042/tm255424d9_ex4-2.htm)[.](https://www.sec.gov/Archives/edgar/data/765880/000110465925014042/tm255424d9_ex4-2.htm) | | | | | | Current Report on Form 8-K | | | | | | February 14, 2025 | | |

New in FY2025

| 4.4.2 | | | | | | [Second Supplemental Indenture, dated August 14, 2025, by and among Healthpeak OP, LLC, the Guarantors, and U.S. Bank Trust Company, National Association, as trustee](https://www.sec.gov/Archives/edgar/data/765880/000110465925078628/tm2522422d7_ex4-1.htm) | | | | | | Current Report on Form 8-K | | | | | | August 14, 2025 | | |

New in FY2025

| 10.3.1 | | | | | | [Amendment No. 1 to Third Amended and Restated Credit Agreement, dated as of October 3, 2025, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., DOC DR Holdco, LLC, DOC DR, LLC, the lenders listed therein, and Bank of America, N.A., as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000162828025046273/ex10109302025.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | October 24, 2025 | | |

New in FY2025

| 10.4.5 | | | | | | [Fifth Amendment to Third Amended and Restated Credit Agreement, dated as of October 1, 2025, by and among DOC DR, LLC, DOC DR Holdco, LLC, Healthpeak Properties, Inc., Healthpeak OP, LLC, the lenders listed therein, and KeyBank National Association, as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000162828025046273/ex10309302025.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | October 24, 2025 | | |

New in FY2025

| 10.5.4 | | | | | | [Amendment No. 4 to Term Loan Agreement, dated as of October 3, 2025, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., DOC DR Holdco, LLC, DOC DR, LLC, the lenders listed therein, and Bank of America, N.A., as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000162828025046273/ex10209302025.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | October 24, 2025 | | |

New in FY2025

| 10.6.3 | | | | | | [Amendment No. 3 to At-the-Money Equity offering Sales Agreement, dated February 6, 2025, among Healthpeak Properties, Inc., Healthpeak OP, LLC, the Sales Agents, the Forward Sellers and the Forward Purchasers.](https://www.sec.gov/Archives/edgar/data/765880/000162828025019948/ex10203312025.htm) | | | | | | Quarter Report on Form 10-Q | | | | | | April 25, 2025 | | |

New in FY2025

| 10.14* | | | | | | [E](https://www.sec.gov/Archives/edgar/data/765880/000162828025020273/employeestockpurchaseplan.htm)[mployee Stock Purchase Plan (adopted in 2025).](https://www.sec.gov/Archives/edgar/data/765880/000162828025020273/employeestockpurchaseplan.htm) | | | | | | Current Report on Form 8-K | | | | | | April 28, 2025 | | |

Dropped from FY2024

| 10.11.5* | | | | | | [Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based LTIP Unit Agreement (adopted 2023).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10803312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

Dropped from FY2024

| 10.11.6* | | | | | | [Form of 2014 Performance Incentive Plan NEO Retentive LTIP Unit Agreement (adopted 2023, for converted 2021 and 2022 LTIP awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10903312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

Dropped from FY2024

| 10.11.7* | | | | | | [Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based LTIP Unit Agreement (adopted 2023, for converted 2021 and 2022 LTIP awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101003312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

Dropped from FY2024

| 10.11.8* | | | | | | [Form of 2014 Performance Incentive Plan NEO Retentive LTIP Unit Award Agreement (adopted 2023, for converted awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101103312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

Dropped from FY2024

| 10.11.9* | | | | | | [Form of 2014 Performance Incentive Plan Non-NEO LTIP Unit Award Agreement (adopted 2023, for converted awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101203312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

Dropped from FY2024

| 10.12.7*† | | | | | | [Form of 2023 Performance Incentive Plan Non-NEO OP Unit Award Agreement (adopted 2025, for converted awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex1012712312024.htm) | | | | | | | | | | | | | | |

Item 16. Form 10-K Summary

15 rewritten, 0 added, 0 removed, 20 unchanged

Read the full itemFY2025 item · filed February 3, 2026FY2024 item · filed February 4, 2025

Rewritten

Dated: February [removed: 4, 2025][added: 3, 2026]

Rewritten

| /s/ SCOTT M. BRINKER | | | | | | President and Chief Executive Officer, Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ [removed: PETER A. SCOTT] [added: KELVIN O. MOSES] | | | | | | Chief Financial Officer | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| [removed: Peter A. Scott] [added: Kelvin O. Moses] | | | | | | (Principal Financial Officer) | | | | | | | | |

Rewritten

| /s/ SHAWN G. JOHNSTON | | | | | | Executive Vice President and Chief Accounting Officer | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ KATHERINE M. SANDSTROM | | | | | | Chair of the Board | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ JOHN T. THOMAS | | | | | | Vice Chair of the Board | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ BRIAN G. CARTWRIGHT | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ JAMES B. CONNOR | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ R. KENT GRIFFIN, JR. | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ PAMELA J. KESSLER | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ SARA G. LEWIS | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ AVA E. LIAS-BOOKER | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ TOMMY G. THOMPSON | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |

Rewritten

| /s/ RICHARD A. WEISS | | | | | | Director | | | | | | February [removed: 4, 2025] [added: 3, 2026] | | |